Methodological guidelines to estimate the prevalence of problem drug use on the local level. by Hartnoll, Richard et al.
  
 
 
 
 
 
 
 
 
 
 
 
Methodological Guidelines to Estimate the 
Prevalence of Problem Drug Use on the Local 
Level 
 
 
CT.97.EP.05 
 
 
Centre for Drug Misuse Research:  Gordon Hay 
      Neil McKeganey 
 
EMCDDA:     Lucas Wiessing 
      Richard Hartnoll 
 
Other Contributors:    Pierre-Yves Bello 
      Daniela D’Ippoliti 
      Antònia Domingo-Salvany 
      Martin Frischer 
      Ludwig Kraus 
     Filip Smit 
 
      
 
 i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please use the following citation: 
 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).  
Methodological Guidelines to Estimate the Prevalence of Problem Drug Use 
on the Local Level. Lisbon: EMCDDA, December 1999. 
 
Since the initial production of these guidelines, the preferred age ranges used 
by the EMCDDA have changed to 15 - 24, 25 - 34 and 35 - 64 (or 15 - 64). 
This report has been updated in the light of these changes, December 1999.  
 
 
 
 
 
 
 
 
 
 
Contact Details 
 
Centre for Drug Misuse Research, University of Glasgow 
Glasgow, G12 8QG 
United Kingdom.  
 
 
European Monitoring Centre for Drugs and Drug Addiction 
Rua Cruz de Santa Apolónia 23/25 
1100, Lisboa 
Portugal. 
 
Further copies of this report can be obtained from the EMCDDA at the above 
address.    
 ii 
 
 
 
 
 
 
 
Acknowledgements 
This publication is based on an EMCDDA-commissioned project which 
examined methods for estimating the prevalence of problem drug use at the 
local level. During this and a previous project, the authors relied on the support 
of researchers throughout the European Union and within the EMCDDA. It 
would not have been possible to conduct local prevalence estimation projects 
without the support of various agencies and bodies which supplied data on 
drug use in the participating cities. The authors would like to acknowledge the 
following individuals who contributed to these projects: 
Catherine Comiskey, Sofia Friere, Maria Moreira, Alvar Norén, Päivi 
Partanen, Kathy Politikou, Dan Seidler, Jaap Toet, Alfred Uhl and Ari 
Virtanen. 
 iii 
 
 
 
 
 
 
 
Contents 
 
 
  Page No  
1  Introduction ......................................................................... 1 
 1.1  Why Estimate Prevalence? ...................................... 1 
 1.2 Why This Publication?............................................. 2 
 
2 Drug Misuse Prevalence Estimation ................................... 4 
 2.1 Case Definitions....................................................... 4 
 2.2 Epidemiological Definitions .................................... 8 
 2.3 How to Estimate Prevalence .................................... 8 
 
3 Methodological Guidelines ............................................... 16 
 3.1 Identifying Data Sources........................................ 16 
 3.2 Negotiating Access to Data Sources ...................... 22 
 3.3 Data Collection ...................................................... 23 
 3.4 Data Collation ........................................................ 28 
 3.5 Data Analysis ......................................................... 31 
 3.6 Dissemination of Results ....................................... 32 
 3.7 Summary................................................................ 34 
 
4 Statistical Analysis ............................................................ 35 
 4.1 Capture-recapture Data .......................................... 35 
 4.2 Log-Linear Models ................................................ 36 
 4.3 Model Selection ..................................................... 37 
 4.4 Confidence Intervals .............................................. 38 
 4.5 Analyses using GLIM ............................................ 39 
 4.6 Analyses using SPSS ............................................. 44 
 
5 Discussion and Conclusions.............................................. 48 
 5.1 Methodological Issues ........................................... 48 
 5.2 Refinements ........................................................... 50 
 5.3 Conclusions............................................................ 51 
 
6 References ......................................................................... 53 
 
 
 APPENDIX I......................................Analyses using GLIM 
 APPENDIX II...................................... Analyses using SPSS 
 1 
 
 
 
 
 
 
 
1 Introduction 
‘How many people use illicit drugs?’ is a question which is deceptively easy to 
ask but notoriously difficult to answer. To examine the tools which were 
available to answer this question a scientific seminar was organised by the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and 
the Pompidou Group of the Council of Europe. This seminar came to be 
known as the Strasbourg Seminar and a collection of the presented papers 
formed the basis of a Scientific Monograph. (EMCDDA, 1997a). 
Methodological advances have been made since then, including an EMCDDA-
funded comparative pilot study in which estimates of the prevalence of opiate 
use were obtained in seven European Union cities using the capture-recapture 
method (EMCDDA, 1997b). That study brought together a range of experts 
from throughout the European Union, and the experienced gained from 
undertaking prevalence studies in these, and other, locations has now been 
channelled into producing methodological guidelines. 
1.1 Why Estimate Prevalence? 
It is difficult to overestimate the importance of obtaining accurate information 
on the prevalence of illicit drug use. Such information is valuable both in 
terms of monitoring the impact of drug misuse at both national and local levels 
as well as in assessing the effectiveness of drug prevention efforts. Drug 
misuse, and the policy response to it, transcends national boundaries and 
therefore the EMCDDA needs to inform policy makers across Europe with 
information on the nature and extent of drug use in different settings. This can 
only be done using comparable methods across Europe, using similar 
definitions and applying the same methodology. It is only then that meaningful 
comparisons can be made between cities within a country, and also across 
countries.  
There is a triangular nature to information on the nature and extent of drug 
misuse at the local level; information is needed to examine how well existing 
drug treatment agencies are providing services for their clients and how the 
needs of the unknown number of drug users can be met. Despite the 
importance of such information, data on drug misuse is often fragmented, 
ranging from local studies of problematic drug use, such as heroin injecting, 
through to national surveys providing information on levels of cannabis use, 
particularly by younger people. While such surveys have provided valuable 
information on the prevalence of certain kinds of drug misuse e.g. cannabis, 
ecstasy and hallucinogens, they are less well suited to estimating prevalence at 
the more problematic end of the spectrum, particularly at the local level.  
The use of ‘heavier’ drugs such as heroin is a hidden and stigmatised activity, 
the details of which many individuals are unwilling to reveal to others, 
particularly those whom they perceive as representing official authority. Drug 
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use is also an activity which for the most part occurs outside the domains of 
the health care and criminal justice systems. It should therefore be remembered 
that, no matter what approach to prevalence estimation is taken, the picture 
produced by this process can only ever be an imperfect approximation of the 
real state of affairs. As a result, our knowledge of the world of illicit drug use 
and our ability to estimate the number of people using illicit drugs within a 
locality is less complete than we may judge to be desirable. 
1.2 Why this publication? 
In this publication we describe methods for estimating the prevalence of drug 
misuse at the local level, in particular the capture-recapture method. We begin 
in Section 2 by providing a summary of the prevalence estimation techniques 
that can be used, ranging from systematically counting drug users through to 
applying more advanced statistical techniques. We then describe the process 
that is undertaken during a capture-recapture study in Section 3 and present a 
series of guidelines which will be useful for those intending to carry out a 
capture-recapture study. At this stage we only touch on the more technical 
aspects of the methodology, leaving a more statistical description to Section 4. 
This section may only be of interest to those with a statistical background and 
it includes annotated output from two statistical packages that can be used to 
analyse capture-recapture data. A related publication provides a scientific 
review of the literature on drug misuse prevalence estimation methods at the 
local level. 
Methodological guidelines, such as those presented within this publication, are 
necessary for several reasons. The range of expertise across Europe is broad; in 
some areas there are experienced research groups which, in addition to 
applying the methods in a range of settings, are contributing to the 
development of the methods. In others areas there are those with an interest in 
how estimates of the prevalence of drug misuse can be obtained but may not 
have the experience. All across Europe however, there will be policy makers 
and professionals who require accurate information on the nature and extent of 
drug misuse in their area and may be considering initiating prevalence 
research. 
Much of what is presented within this publication arises from two consecutive 
EMCDDA-funded projects. The first was a pilot study in which the prevalence 
of opiate use was estimated in seven European cities; Dublin, Helsinki, Rome, 
Rotterdam, Setúbal, Toulouse and Vienna. The second project sought to make 
the experience gained within this methodological pilot study more accessible 
and understandable to those interested in carrying out a drug misuse 
prevalence estimation study in their local area. The three main objectives of 
that project were to produce a set of methodological guidelines of the use of 
capture-recapture methods, to produce a review of the related scientific 
literature, and to provide support to new and existing local prevalence 
estimation studies. The results of the pilot project have previously been 
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presented (EMCDDA, 1997b), however this publication provides a more in-
depth discussion of local prevalence estimation. 
It would be convenient if this publication could give precise answers to all the 
questions that may arise during a prevalence estimation project. Unfortunately, 
there are seldom clear answers in the field of drug misuse epidemiology. These 
methodological guidelines will however give the reader an insight into drug 
misuse prevalence estimation at the local level and will lead the reader through 
the process of obtaining prevalence estimates using capture-recapture methods. 
Some questions will remain unanswered, therefore it may be necessary to forge 
links with research groups who have experience in applying the method, or at 
least with statisticians versed in similar methods. In that sense, prevalence 
estimation methods are not a ‘black box’ which readily produce valid 
estimates. 
It is hoped that this publication will appeal to a wide audience, ranging from 
policy makers interested in initiating a local prevalence study to those who are 
responsible for collecting, collating and analysing the data. Clearly this 
publication cannot comprehensively describe all aspects of epidemiological 
statistical analysis, however it is structured such that an understanding of the 
relevant issues can be gained by the non-expert.  
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2 Drug Misuse Prevalence Estimation 
In this section we describe the different methods that can be use to estimate the 
prevalence of illicit drug use at the local level. Although we use the term ‘drug 
misuse prevalence estimate’ to encompass a range of tools for estimating the 
size of different drug using populations, we begin by exploring the various 
definitions, the drugs that are used throughout Europe and some of the related 
terminology. 
2.1 Case Definitions  
There are a range of terms that are applied, often interchangeably, to describe 
the illicit use of drugs. Some terms are medical in nature, for example drug 
injecting or drug dependence. It is clear that someone who injects drug can be 
classified as a drug injector and medical opinion can define what dependence 
is, for example the International Classification of Diseases (ICD10) codes refer 
to dependence syndrome as: 
‘A cluster of behavioural, cognitive and physiological phenomena 
that develop after repeated substance use and that typically include 
a strong desire to take the drug, difficulties in controlling its use, 
persisting in its use despite harmful consequences, a higher priority 
given to drug use than other activities and obligations, increased 
tolerance and sometimes a physical withdrawal state. The 
dependence syndrome may be present for a specific psychoactive 
substance, for a class of substances or for a wider range of 
pharmacologically different psychoactive substances’ 
The term ‘drug addiction’ is often used interchangeably with ‘drug 
dependence’. In Spain, the SEIT information system additionally defines ‘drug 
abuse’ as 
‘A non-adaptive model of psychoactive substance use, with 
continuous or recurrent use, which does not meet the criteria for the 
diagnosis of dependence of said substance’ 
Other terms can be more subjective, for example ‘problem drug user’. The 
Regional Drug Misuse Databases within the United Kingdom use the 
following definition of a problem drug user: 
‘Any person who experiences social, psychological, physical or 
legal problems related to intoxication and / or regular excessive 
consumption and / or dependence as a consequence of his / her own 
use of drugs or chemical substances.’ 
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This wider definition includes legal problems, albeit only in relation to 
intoxication, dependence or excessive use. Laws on illicit drug use vary across 
Europe relating to the consumption, possession or supply / trafficking of drugs, 
therefore the concept of a legal problem relating to drugs will vary across the 
continent. Indeed, the inclusion of supply, or even possession, within a ‘legal 
problem’ classification could encompass those that do not consume drugs, but 
only supply them to others. 
Definitions such as problem drug use are often intrinsically linked to the nature 
of the drugs that are being consumed. We therefore detail some of the drugs 
that are used throughout Europe. 
Heroin 
The use of heroin appears to be the most problematic drug use in the majority 
of European settings. This opiate can be consumed in several ways, including 
heating the drug on foil and inhaling the fumes; ‘chasing the dragon’, or by 
dissolving the drug and injecting it. The most popular route of choice of 
consuming the drug may vary within and between countries. Tolerance and 
physical dependence can result from regular use of the drug, and withdrawal 
can be difficult. In some areas, the vast majority of drug users contacting 
services are heroin users, the most common form of treatment is often 
substitute prescribing with Methadone. 
Methadone, other opioids and benzodiazepines 
Methadone is a synthetic opiate (opioid) which can either be in tablet or liquid 
form. As it can be used as a substitute for heroin, it can be legally possessed 
with a prescription. Questions have arisen about the efficacy of substitute 
prescribing, with some people continuing to use heroin when they are using 
methadone. Prescribed methadone can also ‘leak’ onto the street and be used 
illicitly. Other opioids, manufactured for medical use, include dihydrocodeine 
(DF 118s), pethidine, Diconal, Palfium and Temgesic. Because of the severity 
of addiction to heroin, some users will resort to using any opiate when heroin 
is not available or they may use benzodiazepines such as diazepam or 
temazepam. These tranquillisers are often prescribed to treat anxiety and as 
sleeping tablets. They can be equally addictive, even when being prescribed 
medicinally.  
Amphetamines and Cocaine 
Amphetamines are synthetic stimulants which can be snorted or injected. In 
Nordic countries, particularly Sweden and Finland, the problematic use of 
amphetamines is more prevalent than that of heroin. Amphetamine use in 
some countries can be paradoxical; it may be one of the most popular drugs 
that are injected, but it can also be one of the most popular drugs used by 
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younger people within dance events with national surveys suggesting that up to 
16% of younger adults have used amphetamines. Indeed amphetamine 
injectors may perceive themselves to be different to opiate injectors and 
therefore be less likely to attend treatment services or needle exchanges. 
Cocaine is also a stimulant that can be snorted, however it is more expensive 
than amphetamines and is therefore associated with a rich lifestyle. Crack is a 
smokeable form of cocaine, and has become a major problem in North 
America. The use of crack has not yet been seen to be as widespread in 
Europe. 
Other synthetic drugs and cannabis 
There are a collection of drugs, including MDMA (ecstasy), LSD and newer 
drugs such as ketamine which are sometimes described as ‘recreational’ drugs 
or hallucinogens. The use of these drugs is certainly not without problems 
however their use is rarely perceived to be as problematic as opiates or 
amphetamines. The use of cannabis also is also rarely seen as problematic. The 
legal response to these drugs varies throughout Europe, in particular there is a 
distinction between ‘soft’ and ‘hard’ drugs in the Netherlands. 
This summary of the various drugs that are used within Europe has been brief, 
however necessary before we discuss prevalence estimation. The question 
‘how many people use drugs’ needs to be refined and a case definition 
established before conducting a prevalence study. In many instances, the use of 
drugs such as cannabis or ecstasy will fall outside the remit of a prevalence 
study, partly due to the less serious nature of the use of these drugs but also 
because of the availability of information about the prevalence of use from 
other sources, such as national surveys. Developing a case definition, in 
relation to the use of more problematic drugs, may be more difficult. 
There has to be a balance, in terms of the drugs included in a case definition, 
between the need to know how many people are users and the availability of 
information. While it may be useful to know precisely how many people are 
drug injectors, perhaps in relation to the spread of HIV or hepatitis through 
shared injecting equipment, in may not be possible from the available data to 
identify which drug users in contact with services or detained by the police 
actually inject. Indeed, the injecting of steroids may possibly be within the 
remit of some prevalence studies as steroid injectors can be at risk of blood 
borne diseases. 
Sometimes this balance may be more of a compromise, particularly with a case 
definition such as problem drug use. For example, although the injecting of 
amphetamines may be as worrying as the injecting of heroin, the other role of 
amphetamine as a dance drug may mean that information on those detained by 
the police for possession of amphetamine may not always be useful. Even a 
wider definition, such as the use of opiates, cocaine or amphetamines, may 
cause difficulties within a prevalence estimation study due to the social and 
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behavioural variability of those that use amphetamines.  
It is sometimes methodologically easier to restrict the analysis to a 
homogeneous group of drug users, such as opiate users or opiate / 
benzodiazepine users. Members of this group could be perceived as the 
stereotypical ‘junkie’ – unemployed, drifting in and out of treatment and in 
trouble with the police. While stereotyping people in this manner can be both 
offensive and unconstructive, it removes the problem of having to distinguish 
between problematic and non-problematic use of drugs such as amphetamines. 
Whatever case definition is used within a local prevalence study has to depend 
on both the nature of drug use in that locality and the availability of data. Drug 
misuse is a transient activity and it should be recognised that an individual’s 
drug use may vary within a short time period. Many drug users will use more 
than one drug, particularly when the availability of their preferred drug is 
limited. Although it is easier to apply the methodology using some case 
definitions, it is, however, not until the analysis stage that a particular case 
definition is found to be the most amenable to analyse. One remedy would be 
to collect as much data as possible in as detailed a form as possible, perhaps by 
collating information on all non-cannabis offenders and all drug users 
contacting services and noting the drugs that these individuals use. At a later 
stage can those who use certain type of drugs be extracted and analysed. The 
decision as to which data should be collected can only be taken at the local 
level and will additionally depend on the resources available to collect data 
and the format it comes in. 
There are different terms used to describe the illicit use of drugs 
 
• addiction 
• problem drug use 
• drug dependence 
• drug use / drug injecting 
 
Many drugs can be used illicitly 
 
• heroin 
• methadone 
• amphetamines 
• recreational drugs 
• cannabis 
 
There should be clarity in what a prevalence estimate refers to 
2.2 Epidemiological Definitions  
Before going on to describe the different methods of obtaining information on 
the prevalence of substance misuse, it is worthwhile to discuss some of the 
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epidemiological concepts used in prevalence estimation, 
The prevalence of a certain social attribute is defined as the proportion of 
people possessing that attribute. It is often expressed as a percentage, or 
sometimes as ‘per thousand’ or even ‘per million’ of the total population. The 
actual number of individuals is sometimes used instead of the prevalence, 
however without information on the baseline population, this number may be 
meaningless. If there are an estimated 1,000 drug users in one city and 2,000 in 
another city, without knowledge of the relative sizes of these two cities, the 
two figures cannot be directly compared.  
When discussing percentages, care must also be taken in the different 
interpretation of the baseline population. Drugs are more commonly used by 
people in the 15 to 34 age group. That is not to say that children under 15 or 
people aged 35 or over do not use drugs, but when calculating a percentage, 
the age range of the baseline population is often one which includes those that 
are more likely to use drugs; using the total population as a baseline would 
therefore result in a lower prevalence value. This is often the case when a 
sample of people are asked about their drug use. If  the sample are 
predominantly in the 15-34 age group, then the proportion currently using 
drugs would probably be greater than that in the 15-64 age group. When 
studies have been carried out in more than one location, differences in the age 
structure of the general population could distort comparisons. 
The concept of prevalence also requires some indication of the time period that 
is being examined. Drug misuse can be a transient activity such that someone 
using drugs one month may not be using them the next, therefore the concept 
of current use may refer in different contexts to use within the past week, past 
month or past year. In addition, lifetime usage can be described, therefore care 
must be taken in comparing lifetime usage between different age groups, given 
that older people may have had a longer time to have used drugs. 
2.3 How to estimate prevalence 
Estimating the prevalence of drug use, particularly problem drug use such as 
opiate use or opiate injecting, is not always an easy task. What begins as a vast 
array of confusing, sometimes conflicting information can apparently be turned 
into a reliable estimate, often with a confidence interval giving added 
statistical credence. However, every estimate produced is subject to caveats or 
assumptions. If these assumptions are not valid, then the estimate may be 
inaccurate. The possibility of inaccuracies in prevalence estimates is often 
more obvious in more straightforward methods, for example when a researcher 
stands on a street corner with a clipboard, asking passers by if they take drugs. 
It is less obvious however, that an advanced statistical technique, such as the 
capture-recapture method, can produce erroneous estimates due to violation of 
some of the assumptions. 
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We begin by describing the use of surveys in prevalence estimation. We then 
discuss enumeration, which is a direct method of estimating the prevalence of 
drug use in which the number of know drug users is obtained by combining 
data from various sources and eliminating the double counting caused by 
overlaps between data sources. An indirect method known as capture-recapture 
can use these overlap data, along with the number of known drug users to 
estimate the size of the unknown drug using population. Other indirect 
methods which can be considered include network analysis techniques such as 
snowball sampling or multiplier techniques. 
Surveys 
General population surveys which provide information on the use of drugs at 
the national level have been carried out in several countries of the European 
Union, including Belgium, Denmark, Germany, Spain, France, Finland, 
Sweden and the United Kingdom. These population surveys can either be 
specific surveys on drug use, or more general health related or crime surveys. 
They can assess the nature and extent of drug misuse and often provide 
information on respondents’ recent or lifetime drug use.  
There is the methodological problem that general population surveys are less 
likely to include harder to contact people who may be more likely to be 
problem drug users, in particular sub-populations such as the homeless or 
those living in institutions. People may be reluctant to divulge information on 
matters which are deemed to be socially unacceptable, therefore general 
population surveys may be more appropriate in assessing the prevalence of 
recreational drug use, but not for problematic use. In addition very few people 
use drugs such as heroin therefore detecting the use of such drugs within a 
general population survey is quite difficult. There are, in addition, the 
problems relating to people wrongly filling in the questionnaires such that one 
or two incorrectly completed questionnaires may, in small surveys, exaggerate 
the use of certain drugs and in some cases the sample sizes needed to obtain 
worthwhile results often make the costs of sampling prohibitive. 
The scope of a general population survey may mean that local variations in 
levels of drug use are not usually identified. Thus a survey may be useful in 
evaluating a national health promotion campaign about the use of drugs such 
as ecstasy, but will be of little use in deciding where to situate a needle 
exchange. 
There can sometimes be benefits of using surveys. For example information on 
the use of drugs by younger people can be gathered by surveys of 
schoolchildren. National school surveys are more common within the 
European Union. It is often easier to get a representative sample, and repeated 
surveys or surveys of different age groups can describe trends in drug use. 
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Although general population surveys can suffer difficulties in reaching a 
representative sample, surveys of specific populations can be undertaken. 
These can either examine groups of people that may be more likely to be drug 
users, for example those detained for crimes such as theft, those in prison or 
those that attend emergency rooms. Such surveys will not, in themselves, 
provide estimates of the level of drug use in the more general population, but 
may provide data for other prevalence estimation methods. Specific surveys of 
drug users can also be undertaken, either to gain behavioural information such 
as route of administration, injecting or needle sharing, or medical information 
such as the prevalence of HIV or hepatitis. 
Enumeration 
There are a range of data sources which can be thought of as indicating the 
number of drug users in a particular locality. These include drug treatment 
agencies, methadone prescribers, needle exchanges, HIV treatment agencies, 
general practitioners, emergency rooms, mobile emergency units, hospitals, the 
police and prisons.  
To use these sources within a prevalence study, it is necessary to obtain 
enough information from each data source to identify each individual drug user 
and thus to eliminate double counting. This requirement has to be weighed 
against the confidentiality requirements of each source. Hence initials, sex and 
date of birth are often used to sift out multiple occurrences. It should, however, 
be noted that collating information from data sources using this un-named 
identifier information can be imprecise, especially as the accurate collection of 
names and dates of birth may not be the highest priority for some agencies 
working with drug users. This exercise can be useful in describing the known 
drug using population. 
Data from the sources listed above (usually with the exception of the police 
and prisons) are often required to collate registers, particularly those relating to 
drug users in treatment,  for example the SEIT reporting system in Spain, the 
IVV/LADIS reporting system in The Netherlands, the RELIS/LINDDA 
reporting system in Luxembourg and the Regional Drug Misuse Databases in 
most of the United Kingdom. The police also collate information in many 
countries of the European Union, however just as any increase or decrease in 
the number of people entering treatment may be partly due to the increased 
availability of treatment or its effectiveness, any increase or decrease in the 
number of drug-related arrests may only reflect operational decisions of the 
Police. Even if these registers were highly correlated with the prevalence of 
drug use, by their definition they can only be taken to be describing the 
numbers of drug users in treatment or the level of detected drug-related crime. 
Clearly the spectrum of drug using behaviour is not restricted to those who are 
in treatment or are have been detained by the police. 
Case-finding studies are a more systematic form of multi-source enumeration 
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in which agencies, such as those detailed above, contribute identifier data on 
drug users. The identifier data can again be used to sift out double counting 
and as total coverage of all possible sources is aimed for, the total number of 
known drug users can then be calculated. In many areas of Europe this total 
coverage is not feasible and other problems such as difficulties in identifying 
double counting serve to make this method impractical. Sweden, however, has 
a long tradition of case-finding (Olson, 1997). 
Information on the nature and extent of the unknown population of drug users 
is also required to give the complete picture of drug use, and in particular the 
size of the unknown population of drug users is needed to obtain an estimate 
of the total number of drug users. There are several different ways of doing 
this, as described below. 
Capture-recapture and multiplier techniques 
A methodology, commonly referred to as capture-recapture, has increasingly 
been used to estimate the prevalence of drug misuse. As the name alludes to, 
this methodology was originally developed by ecologists who were interested 
in estimating the size of animal populations. Two analogous examples are 
presented here; one from ecology, and one from an early application of 
capture-recapture in estimating the prevalence of drug misuse. 
An ecologist wants to estimate the number of fish there are in a lake: therefore 
a sample of fish are caught, counted, marked in some way and then released. 
We show this in Figure 2.1, where a sample of 15 fish have been caught and 
marked. At a later date, the ecologist returns to catch another sample, and by 
checking for marks (as demonstrated in Figure 2.2), the number of fish seen in 
both samples is discovered and thus the ratio of previously caught to 
previously uncaught fish in the second sample can be found. As it can perhaps 
be assumed that the ratio of caught to uncaught in the first sample is the same 
as the ratio of previously caught to previously uncaught in the second sample, 
the total population size can be estimated by multiplying the number seen in 
the first sample by the inverse of the ratio.  
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Figure 2.1     Figure 2.2 
 
In the example shown in Figures 2.1 and 2.2, initially 15 fish were caught and 
marked in the first sample, and 10 were caught in the second. As five of the 
fish in the second sample bore marks from the first sample, we can perhaps 
assume the ratio found within in the second sample - 5 / 10, is equal to the 
ratio if caught to uncaught fish in the first sample, therefore 
Where x is the total number of fish in the lake – the value we wish to estimate. 
When we re-arrange this equation, we can show that 
Therefore there are 30 fish in the lake. An example which seeks to estimate the 
size of a drug using population may further explain the method. 
Hartnoll et al. (1985) applied the capture-recapture methodology when 
estimating the prevalence of opioid use in an area of London. They collected 
data concerning opioid users who had attended a drug clinic and those that had 
been admitted to a hospital for infectious diseases because of their drug use. 
By comparing these sources of data they found that 20 per cent, or a fifth, of 
the hospital sample had also attended the drug clinic. Thus the total number of 
opioid users could then be estimated to be five times the number who attended 
the drug clinic. Thus the size of the hidden population of drug users was 
estimated by merging two existing sources of data and examining the overlap 
between them. 
These simple examples mask some of the problems of the capture-recapture 
x
15
10
5
=
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1510 =×=x
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methodology. In Hartnoll’s case, if those who are attending in the clinic were 
more likely to have been admitted to the hospital then the resultant figure 
would be an overestimate. Thus, if there is some kind of relationship between 
data sources the estimate could be inaccurate. Unfortunately it is often unclear 
if  such relationships are present and therefore the validity of estimates 
obtained when examining two data sources are often questionable.  
The capture-recapture methodology can compensate for this problem by 
employing three or more sources. The extra information present in the third 
sample can be used to examine whether or not there are any relationships 
between data sources, and if they are, the estimate of the total population size 
can be adjusted accordingly. Frischer (1992) used three sources of data which 
held information on drug injectors in the City of Glasgow in 1989. These were 
combined data from treatment agencies, an HIV test register and the Police. In 
total, information was gathered on 1,738 individuals, and the overlap between 
the data sources can be described by Table 2.1.  
Table 2.1. Presence or Absence from Three Data Sources of 1,738 
Drug Injectors. Source Frischer (1992). 
  Police 
  Present Absent 
  Treatment Agencies 
  Present Absent Present Absent 
HIV Present 5 15 109 389 
 Absent 23 366 831 * 
These data can be analysed using statistical packages. In short, the 7 pieces of 
information in this table can be used to predict the missing value, which would 
be an estimate of the number of drug users not present in any of the three data 
sources, or the unknown drug using population. This can by done by log-linear 
analysis. Different relationships between the data sources can be described 
using this analysis, for example if it was thought that those drug injectors 
attending treatment agencies were more likely to have been tested for HIV, 
then this relationship can be included. The decision to include any 
relationships between sources can be taken by examining how similar the 
observed overlap pattern is to what would be expected if such relationships 
were actually present. Thus different models can be fitted to the observed data 
and a preferred model would be one that closely fits the observed data. 
This methodology has been applied successfully in a range of European 
settings, including Glasgow, Liverpool and Dundee in the United Kingdom 
(Frischer et al., 1993; Squires et al., 1995; Hay and McKeganey, 1995), 
Barcelona, Spain (Domingo-Salvany et al., 1995) and Toulouse, France (Bello 
and Chêne, 1997). The capture-recapture methodology is more 
comprehensively discussed in the next sections of this publication, while a 
description of the historical development and applications of this, and other 
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methods, is to be found in a related publication. 
In a similar manner to the two sample capture-recapture method, the 
prevalence of drug misuse can be estimated by applying a multiplication factor 
to other indicators, in particular data on drug-related deaths. In-depth studies 
of drug use and mortality suggest that 1-2 per cent of drug injectors die per 
annum (Ghodse et al, 1985). Thus taking the upper level, an estimate of the 
number of drug injectors can be found by multiplying the number of deaths in 
the injecting population by 50. The inaccuracy of these estimates reflects that 
the multiplication factors will vary between different areas and between 
different times, leading some to suggest that these factors are little more than a 
guess. 
Other methods 
The capture-recapture method and the multiplier method use available data in 
estimating the prevalence of drug misuse. In some instances, the available data 
can be augmented by data gathered during fieldwork studies. Various terms are 
used to describe these methods, including nomination techniques or network 
analysis. The term ‘snowball sampling’ describes a method of obtaining the 
additional data, in this case by asking drug users to identify others that may be 
interviewed (Korf, 1997). In essence, these techniques are similar to 
multiplication methods, with one source being an existing source such as drug 
users in treatment. The other source would be the data collected during field 
work. Again these methods again rely on assumptions whose validity cannot 
readily be tested, and they may be more time consuming and expensive to 
undertake as opposed to other forms of prevalence estimation. 
There are other advanced statistical techniques that can perhaps be used to 
estimate the prevalence of drug use at the local level, and these are discussed 
in a related publication. Many of them have not yet been applied in Europe, 
and most would require similar data to those used within a capture-recapture 
study. 
Summary 
Various methods for estimating the prevalence of drug use have been 
described above. It is important to note that there is not one ‘best’ method for 
obtaining information on the extent of drug use. The preferred method will 
depend on what way the information will be used. For example, a national 
general population survey would not be useful in determining the prevalence 
of drug injecting within a city. This information will be required by service 
providers at a local level in determining the need for control strategies such as 
needle exchanges or the provision of substitute prescribing. In contrast, a 
national advertising campaign highlighting the problems of ecstasy use will 
rely more heavily on information obtained from national surveys. 
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It is clear that questions relating to the prevalence of drug use cannot simply be 
answered by examining only a few sources of data or relying too heavily on 
one research method. Indeed, information on drug use has been compared to a 
jigsaw with several pieces missing. We have, however, described the pieces of 
the jigsaw that are often available and describe some of the methods that can 
be used to piece together the jigsaw and thus provide the required information 
on the prevalence of drug use. 
There are a range of methods that can be used to estimate the 
prevalence of drug misuse 
 
• surveys 
• enumeration 
• multipliers 
• capture-recapture methods 
• network analysis 
 
Different methods are better used to examine different types of 
drug misuse 
 
There may be no ‘best’ method, rather a combined approach 
 
 
 
 16 
 
 
 
 
 
 
 
3 Methodological Guidelines 
In this section we detail the process that is undertaken when conducting a drug 
misuse prevalence study at the local level. We begin by discussing the sources 
of data on drug misuse, then describe how such data can be collected and 
collated in a form which enables a description of the nature an extent of known 
drug use. The result of that stage of the process is a multi-source enumeration. 
We then briefly describe how this information can then be used to provide an 
estimate of the size of the hidden population of drug users using the capture-
recapture methodology. Because the application of the methodology requires 
some understanding of statistical techniques and experience in the use of 
statistical packages, we leave some of the more statistical aspects of the 
methodology to the following section. It is therefore hoped that this section 
will be understandable to those without a statistical background.  
There are several distinct stages in carrying out a prevalence estimation study 
and the skills needed to complete each stage are varied, ranging from the 
concise recording of identifier and other information within a manual data 
collection exercise, the manipulation of data using a spreadsheet, through to 
advanced statistical analysis. We shall now detail each stage of this process. 
3.1 Identifying data sources 
Despite the illicit use of drugs being a covert activity, it remains a legal, social 
and medical problem and results in drug users coming into contact with a 
range of agencies and services, including drug treatment agencies and the 
police. These agencies, to a varying extent, collate information on drug users 
that they have been in contact with. Sometimes this is a legal requirement, for 
example there are registers of drug users in treatment in many countries. In 
other instances the data collated on clients depends on the operational policies 
of the agencies. The reasons why and individual will appear within a data 
source will also vary between sources; it can be argued that those drug users in 
contact with drug treatment services are a self-selecting group, whereas those 
that have been arrested for drug offences may be more representative of the 
total drug using population. 
Clearly, since prevalence estimation methods rely on obtaining accurate and 
relevant information from various data sources, a description of the various 
sources of information on drug misuse is important. We therefore describe the 
data sources that have been used in previous studies in Europe. It should be 
remembered that this is not an exhaustive list, rather a suggestion as to where a 
drug misuse prevalence project should begin to identify possible data sources. 
In the same vein, just because data from a particular kind of agency was easily 
accessible in a previous project, it may neither be possible nor practical to 
collect such information in every instance. Indeed, issues arise as to why 
agencies should co-operate within a drug prevalence study, bearing in mind the 
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confidentiality that they offer to their clients.  
Just as many prevalence estimation methods rely on a minimum standard of 
data in terms of accuracy or relevance, there is often a minimum amount of 
data needed to provide a worthwhile prevalence estimate. Unfortunately, there 
are no definitive rules about the amount of data required by a prevalence study, 
this will depend in part on the nature of the sources and any relationships 
between them. Where possible, as many sources of data should be employed, 
collating as much data as available. This advice, however has to be balanced 
with the financial implications of collecting the data. 
Drug treatment agencies 
Counselling and support of those who have problems relating to drug misuse is 
available from a diverse range of agencies throughout Europe and the range of 
services offered by such agencies is equally diverse. Many drug treatment 
agencies will collate records on clients in similar manner to the way a hospital 
or a general practitioner would complete medical records. Often within these 
records, an assessment of a client’s drug use will have been made, particularly 
when they have first contacted the service or returned to the service after a 
period of non-contact. This potentially could be the only information on a 
client’s drug use that is available, and as such could be flawed. Only an ardent 
optimist would assume that a drug treatment service is so efficient that all of 
those presenting with a severe problem, for example heroin injecting, will 
rapidly alter the nature of their drug use. However, only a pessimist would 
assume that a drug treatment service is so inefficient that their clients’ drug use 
would not change during their time in contact with the service. 
The Surveillance System on Drug Addiction in Rome gathers 
information on drug users attending public treatment centres. 
It collects socio-demographic information on patients and the 
treatment offered. This data source covers the whole of the 
city and included over 6,000 individuals. It was used within a 
three-sample capture recapture study in 1997. 
Low threshold agencies 
There may be other agencies which operate in more relaxed manner, for 
example drop-in centres or needle and syringe exchange schemes. Such 
services often view drug misuse, and therefore the treatment of drug misuse as 
a social rather than a medical problem, and thus could be attracting a more 
representative group of drug misusers. These agencies may collate the same 
standard of information on their clients as the more formal drug treatment 
agencies described above, although in some instances they are more relaxed 
and some clients may only be known by a forename or an assumed name.  
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Intermède, in Toulouse, is a low threshold agency which 
opens each afternoon. Drug users can drink coffee, have a 
shower or use a laundry, while having access to a needle 
exchange and to social workers. The data collated by this 
agency was combined with other similar agencies within a 
three-sample capture recapture study in 1997. 
Methadone prescribing services 
In some areas the prescribing of methadone as a substitute to heroin will be 
organised separately from drug treatment services. As methadone is also a 
opioid and can be highly addictive, data concerning individuals being 
prescribed methadone are usually of a high quality. Even where more than one 
agency (including treatment agencies or general practitioners) are able to 
prescribe methadone, a central register may be in existence to prevent an 
individual obtaining methadone from more than one source. The nature of 
these data, in particular the serial nature of repeat prescribing, would reduce 
the problem of only being able to assume that such individuals are opiate 
users.  
An additional point to note about substitute prescribing, particularly 
methadone prescribing, is that the legal problem which some users had 
previously faced should have been removed. This may not be a sufficient 
justification for removing methadone from the remit of a drug misuse 
prevalence study particularly because of the illicit use of methadone by those 
without prescriptions and the continuing use of other opiates by those in 
possession of a prescription. It can, however, cause difficulties in analysing 
data as some methadone users should be less likely to be in contact with the 
police. 
The Central Patient Methadone Treatment List, in Dublin, is 
maintained by the Department of Health. It records those 
who receive methadone prescriptions from either a 
specialised clinic or a general practitioner. From this list it is 
possible to determine how many times, when and for how 
long each individual was on methadone. The data on over 
3,000 individuals was used within a prevalence estimation 
study in 1997. 
These last three headings have been a convenient way to summarise various 
types of drug treatment agencies that may exist in a city. In some areas, these 
three types of service may be provided by the one agency, in other areas 
similar services are provided by a range of agencies. While some of these 
agencies may only cover  specific geographical areas of a city there may, in 
other instances, be duplication in the provision of service. Within a prevalence 
project it therefore may be necessary to combine data from different sources 
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into a single ‘treatment’ source. The decision to do this may be taken at the 
analysis stage of the project, therefore data from distinct agencies should be 
recorded as such during the data collection process. 
Other Medical Services 
Drug users, particularly drug injectors, are often are subject to higher rates of 
morbidity and mortality. Some problems can be dealt with at a drug treatment 
agency, or advice given that reduces the contact with other services that a drug 
user may have, such as information on safer injecting to reduce the risk of 
abscesses. Other problems may result in drug users contacting medical services 
such as emergency rooms, HIV / hepatitis related services, clinical 
psychologists, psychiatrists as well as their General practitioner. 
One problem that exists in obtaining information from such sources, is that 
drug users are not the only clients such agencies or professional deal with. 
There may however be existing data collection processes that can be accessed, 
for example a psychiatric hospital admissions recording system which 
routinely records any drug-related admission. General practitioners may collate 
information on drug misusing patients, particularly if they are involved in 
substitute prescribing or are require to contribute to national monitoring 
system.  
This problem can be addressed by setting up a data collection system, either 
prospectively or retrospectively. Either approach will have time and resource 
implications; a system in which the receptionist at an emergency room 
completes a brief form for each patient noting their drug use over a six month 
period would provide useful information within a drug misuse prevalence 
study. This approach would, however, extend the length of time the project 
takes to complete and would need a formal agreement for the emergency room 
to devote valuable time to fill in the forms, perhaps including a financial 
arrangement. To retrospectively examine the records of an agency such as an 
emergency room, could also be time consuming. This approach may be 
favourable as a dedicated data collector would soon become adept a sifting 
through records, perhaps with the aid of a formal screening instrument. What 
may initially appear as an insurmountable stack of records can be 
systematically worked through in a reasonable time period. As with drug 
treatment agencies, issues of confidentiality would have to be resolved prior to 
the data collection process. 
Data sources on HIV or hepatitis may routinely record information such as the 
reason why someone has been tested or behavioural data such as drugs used or 
frequency of sharing injecting equipment. Although these data may be 
comprehensive and easy to collect, it should be remembered that the risk 
behaviour that led to an individual becoming infected may have ceased some 
time previous.  
 20 
 
 
 
 
 
 
 
The following sources have been used within capture-
recapture studies in different locations: 
• Vienna – an Emergency Ambulance which deals with  
‘acute opiate intoxication’ 
• Rome – a Mobile Emergency Unit which deals with 
overdose or withdrawals 
• Helsinki – a Hospital Patient Discharge Register                    
Police 
The legal response to drug misuse varies throughout Europe, with laws relating 
to the consumption, possession or supply of illegal drugs. The police within a 
city may collate these data themselves either for their own use or for national 
statistics or they may allow access to crime reports to enable someone to 
retrospectively collate such data. It should be remembered that there may be a 
difference between being detained in connection with the use of drugs and 
being convicted for a crime. Where available, information on detainees would 
be more useful and any delays in the legal system should not influence the data 
in a prevalence study. 
Just because someone has been found in possession of a drug, it does not 
necessarily mean they use that drug. This point may be more pertinent when 
considering people detained for supplying drugs. Similarly, just because 
someone is detained in connection with one drug, e.g. cannabis, it does not 
mean they do not use more problematic drugs such as heroin. It should also be 
recognised that strategic decisions by the police may influence the chances that 
a drug user is detained for drug offences. Policies may vary within and 
between cities. Therefore although it may be convenient to assume that a 
police sample would be more representative than a treatment sample, it may 
not be. 
Clearly offences relating to the use, possession or supply of drugs are not the 
only reasons why drug users come into contact with the police. To achieve a 
high enough income to support a serious drug problem, many users have to 
commit crimes, and there often exists a relationship between drug use and 
crimes such as theft or shoplifting. In many cases, information on drug users 
that commit these crimes is not collated by the police, although increasingly 
the link between crime and drugs is being examined, one example being the 
use of drugs while driving. 
An individual’s drug use may be noted at other points in the legal system, for 
example when the punishment for the crime is determined. There may be a 
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system in which a report is completed on convicted individuals. This could be 
to establish whether or not a non-custodial sentence is appropriate, for 
example community service or attendance at a treatment agency. This function 
may be undertaken by various agencies, for example a probation service, a 
social service or even a drug treatment agency itself. If an individual does 
serve a prison sentence, the prison may assess whether or not they are a drug 
user, or offer substitute prescribing. Indeed the illicit use of drug often 
continues within a prison. Consideration has to be made as to whether the 
prison population is included within the remit of a prevalence study, although 
short term prisoners who are released back into the community may be of 
interest. 
Police arrest data on possession or supply have been used 
in a variety of locations including Dublin, Helsinki, Toulouse 
and Vienna. In addition, police data in Dublin provided 
information on drug-related crime such as theft, and in 
Helsinki, information on those that had been arrested for 
driving under the influence of drugs has been used in a 
capture-recapture study. 
Summary 
We have described some of the sources of data on drug misuse, particularly 
those which may be of particular value in a drug misuse prevalence study. 
Other data on drug misuse may be available within a locality which may, or 
may not be useful, for example data from a youth service may not be useful in 
a project which specifically examines drug misuse in the adult population. 
When identifying data sources, a balance has to be made between gathering all 
possible information and the time or other resources available. While in some 
areas, case counting exercises have been undertaken which sought to count all 
drug users in contact with all agencies, in many other instances a comprise has 
to be made. Unfortunately, it will not become clear that enough relevant data 
have been collected until the analysis stage of a project.  
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There are a range of sources of information on drug misuse 
 
• drug treatment services 
• methadone prescriptions 
• police 
• prisons 
• emergency rooms 
 
These sources often provide information on 
different types of drug misuse 
 
3.2 Negotiating access to data sources 
A drug misuse prevalence study can only be undertaken with the co-operation 
of those who hold information on drug misuse. Each agency will have its own 
idea about the need or relevance of prevalence research, and each agency will 
have its own concerns about giving access to confidential data. Agencies 
which are not exclusively concerned with drug misuse may see requests for 
information on drug misuse as an additional burden which they may not be 
keen to take on. 
They may also be more political obstacles to collecting data from some 
agencies. Drug misuse is a diverse phenomenon, and the social or medical 
response to it can be varied. Some agencies may not agree with the approach 
that other agencies have to drug misusers and may be apprehensive about 
contributing data to a prevalence project. Often this apprehension is increased 
because of the nature of a research project or its funding. For example a drug 
treatment agency may be uneasy about supplying data to a project undertaken 
by the local police. The independence of the researcher may result in easier 
access to data, particularly when the project is funded by a collection of policy 
makers or service providers which also fund the services which deal with drug 
users. It is also easier to persuade a manager of a service to give access to data 
when their funders have given their approval. 
The main issue which agencies see as a reason for not giving access to their 
data is confidentiality. There could indeed be two distinct issues; the fact that a 
researcher may thus be free to sift through clients records and the fact that data 
can then be used to identify the clients of the agency at a later stage in the 
study. Medical records can be quite detailed, and during their contact with a 
service a drug user may disclose extremely personal information. The 
confidentiality of such information is imperative and drug treatment agencies 
may have reservations about allowing a researcher to have access to the 
records, particularly if there is a possibility that the researcher may know some 
of the agency’s clients. The second issue can be almost entirely resolved by 
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only collating limited information on each client of the agency, as described 
below. 
3.3 Data Collection 
The collection of data within a prevalence study needs to considered as 
important as any other stage in the project particularly as any inaccuracies 
within the data collection process can unduly influence the resultant estimate. 
For this and other reasons it would be preferable to have the same person 
collecting, collating and analysing the data. Clearly this is not always possible, 
therefore those collecting the data should have a knowledge of the 
methodology and how any violations of the assumptions may affect the 
estimate. It may therefore be better to have a small number of people 
collecting data. This may also help in fostering a good working relationship 
between the data collectors and the contributing data sources. In an attempt to 
obtain consistency between the information gathered by different data 
collectors, a screening instrument may be used. This could, for example, 
provide a checklist for inclusion within the study in terms of drugs used or 
length of drug use. In some situations, it may be easier for the data collectors 
to be in regular contact with the researcher who will be analysing the data, 
particularly as some of the problems relating to data collection may not be 
anticipated as they are peculiar to an individual agency. 
As a drug user may be in contact with more than one agency, and therefore be 
included in the data from more than one source, sufficient information is 
needed on each individual to identify multiple occurrences. Matching records 
between data sources can be complex, and within the area of record linkage, it 
is recognised that problems exist even when several different fields of data on 
each individual has been collected. 
To alleviate concerns about confidentiality, many studies have restricted the 
data collection process to the following fields: 
• forename initial 
• surname initial 
• date of birth 
• sex 
These fields of data should be sufficient to identify those that are in contact 
with more than one sources, but there are many problems that may have to 
addressed. 
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To begin with, the possibility that errors in the recorded data exist should be 
acknowledged, for example dates of birth can be easily recorded erroneously, 
perhaps by transposing the month and day of the month. In some cases, the sex 
of an individual may not be obvious and as full names and addresses are 
collated at source; this may be a problem that is peculiar to the prevalence 
estimation project. 
The names recorded by agencies may differ under different circumstances. 
This can partly be due to the culture of a country, for example people having a 
proper name that they would known as by the police, but maybe a middle 
name that they are more commonly known as at a low threshold treatment 
agency. Married women may interchangeably use their married or maiden 
name and people may be able to use an assumed name at some services. The 
data collection process will also be subject to missing data, for example an age 
recorded instead of a date of birth. 
Even if all data were accurately recorded in the same manner at every 
contributing agency, there exists the possibility that two or more distinct 
individuals have the same identifier information. An obvious example would 
be twin brothers who have the same forename initial, however some 
combinations of initials  may be more common than others. 
There may be other ways of identifying which individuals are in contact with 
more than one source, for example Soundex codes which convert a surname 
into a code which can then be matched across agencies. In some areas, a 
common identifier number may be used by more than one agency, e.g. a social 
security number or a health service number. When a single agency undertakes 
more than one service, such as counselling and a needle exchange, they may 
themselves have a method of linking records together which can be used 
within a prevalence study. 
In addition to the identifier information detailed above, information on an 
individual’s drug misuse is required. As previously discussed, there may be 
inaccuracies inherent in these data such as someone found in possession of a 
drug they do not use by the Police. It may be easier to code the drugs used into 
a category, both to save time within the data collection process and to assist in 
the analyses. 
A reference date for the information is useful within a prevalence study to 
assist in analysing the data. For example the date when someone was arrested 
or the date that an initial assessment at a treatment agency was undertaken. 
Care must be taken when an individual appears more than once in a single 
source. A good example would be a person who was detained for drug 
offences during the study period. Care must be taken in sifting out this 
multiple occurrence, particularly if they were  detained for possession of 
cannabis on one occasion and possession of heroin later. Sifting out the heroin 
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instance may remove relevant data. 
Finally, some indication of the area of residence of an individual is useful. 
These geographical data can be used to match individuals, however the 
accuracy of such data may not be sufficient. Rather, the information is useful 
in splitting the study area into different localities and to check that an 
individual actually resides in the study area. This process can often be more 
vague than the matching process, particularly when geographical information 
is not routinely recorded. Once the area has been divided up into various sub-
areas then separate analyses made be performed for each of the smaller 
districts. An additional, more pertinent reason which will be discussed in 
greater detail is that prevalence estimation methods need to assume that those 
being studied are relatively similar, particularly in relation to their contact with 
services. If, for example, drug users for one part of a city were less likely to 
attend a service based at the other side of town, then this assumption would be 
violated. 
Postal code data can also be used as geographical identifier information, 
although a system of identifiers used to speed up the delivery of mail may not 
be the most practical when examining drug use. Often the geographical 
information stored by one agency is in a different format to that of others.  
In many cases, data has to be collected manually, either by pen and paper or 
being typed straight into a laptop computer. This can be a laborious process, 
not particularly due to the amount of data that is required, but more because of 
the logistics of extracting a large file from a filing cabinet, finding the page 
with the relevant information, then replacing the file. There may also be the 
problem of lack of space, with the person collecting the data having to seek 
accommodation near to filing cabinets thus getting in the way of agency staff. 
The work of an agency cannot be put on hold during the data collection 
process, and the files on some clients may be in use during the data collection 
period and thus cannot be accessed. 
Computerised data 
In many instances, the data that are required have already been computerised 
by the agency, although rarely in the form described above. Names need to be 
converted into initials, and the relevant information needs to be extracted from 
a larger computer file. There are many ways of doing this, depending on the 
computer package used to store the data within the agency and the package 
that will be used to collate and analyse the data by the researchers. It is often 
easier for the researcher to obtain a file that includes names and addresses and 
then delete out the names after the initials have been obtained and remove the 
address after postal codes or area of residence have been assigned. This is 
often contrary to the confidentiality requirements of the agency supplying the 
data and therefore staff within the agency may be required to convert their data 
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into a satisfactory format. 
Confidentiality is a key concern to agencies which collate 
information on drug misuse 
 
Un-named identifier information may be collated 
 
• forename initial 
• surname initial 
• date of birth 
• sex 
 
This allows identification of overlaps between data sources but 
preserves the anonymity of clients 
 
As different data sources collate different information and have different types 
of client, it is important to have consistency within the data collected in the 
course of a capture-recapture research project. Several definitions need to be 
employed, relating to the scope of the project:  
Time Period  
Although the capture-recapture method assumes that the number of drug users 
is relatively stable over the time period that is being studied, this time period 
needs to be long enough to give sufficient numbers from each source. In many 
studies, a 12 month period is used, however in some areas where patterns of 
drug use are more fluent, shorter periods perhaps should be employed, such as 
3 months or 6 months. Even when a 12 month period is being examined, it is 
prudent to record drug users identified from different periods within the year, 
for example those who are identified only from the first six months, only from 
the later six months, and those that would be identified from both semesters. 
Thus if there are not a sufficient number of sources available to analyse the 
data using the traditional multi-sample capture-recapture method using distinct 
sources, the two semesters can be modelled as separate sources. This would 
then need to be recognised within the analysis, as it may be assumed to be 
some relationship between the two semesters. 
Age Group  
Drug use is often more prevalent within younger age groups, however as the 
method concentrates on data from sources such as drug treatment agencies 
which do not usually cater for younger drug users, it is sensible to impose a 
lower limit on the age of those included within a study. As population figures 
within cities are usually presented within 5 year age groups, capture-recapture 
studies often stratify the collated data into 15-24, 25-34 and 35-64 groupings. 
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In practice, it is often easier to collect all possible data then extract the data for 
the required age groups in the data cleaning stage of the analysis. As dates of 
birth are often collected to allow identification of overlaps the choice of cut-
off ages for the groups may be taken at a later stage if necessary. 
Area  
Local prevalence estimation studies are usually undertaken in cities, with the 
expectation that the resultant estimate refers to the number of drug users 
resident within the city. Care must therefore be taken to use a consistent 
definition of a city, particularly when the same city name is used 
interchangeably to describe a local government area, a health authority area or 
a conurbation. As previously noted, some degree of geographical information 
should be collected from each contributing data source. This may not be 
necessary if it is clear that each source only collects data from the city, and 
uses the same definition of the city as the prevalence estimation project. 
Similarly, care must be taken that each of the contributing data sources covers 
the whole of the city. If some data sources only cover specific areas of a city, it 
is important to merge similar sources to gain a larger coverage, for example, if 
a city has two drug treatment agencies covering different areas, the data from 
these two agencies should be merged together to obtain a single treatment 
source covering the whole city. If data, even from only one of the contributing 
sources, are only available for one part of the city, then the definition of the 
local area that is being studied needs to be altered.  
We have described above some of the definitions that need to be considered 
when undertaking a local prevalence study. There may be additional issues that 
need to be addressed. For example, we have described how it is important that 
all contributing sources cover the same area and supply information over the 
same time period and use a common age range. In the same vein, a data source 
that only has data on females may not be of immediate use in the analysis.  
The above definitions are usually easy to implement; either an individual is 
within the defined age range or they are not. Other definitions are harder to 
implement, such as those relating to the drugs used by the individual and how 
problematic their use is. But it is just as important that all contributing 
agencies use similar definitions, for example a needle exchange may have 
clients that only use amphetamines, or even clients that only use steroids, 
therefore it would be wrong to use such data within a study which is 
examining opiate use. We will discuss later how even when a strict definition 
(such as opiate use) is common to all sources, variation in the severity of use 
within and between sources may cause problems in analysing the data. 
Comparability of definitions between sources is required 
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• time period 
• age range 
• geographical area 
• drugs used 
• nature of drug use 
 
3.4 Data collation 
Data cleaning 
An initial step in collating the data is to clean the data from each source. This 
process involves removing erroneous data and checking that all individuals 
meet the study criteria, i.e. they use the specified drug(s) and reside in the city. 
It is possible at this stage to produce summary statistics from each source, such 
as the number or clients, the mean age of the clients, the percentage that are 
male or the area of the locality that they reside in. When cleaning the data, a 
decision has to be made concerning records with missing fields, or those that 
have alternatives for a single field, such as a maiden and a married name for a 
female. It may be easier to eliminate all records that are incomplete, however 
where data are scarce, this may reduce the likelihood of obtaining a prevalence 
estimate. It is possible that a single data source may have multiple occurrence 
of the same individual, either in error or because of the nature of the data.  If a 
record with missing fields refer to an individual who is already within the data 
source and a decision is made not to delete the record then the total number of 
people identified from within that source will be inflated. When eliminating 
multiple occurrences from within a single source, care must be taken not to 
eliminate potentially useful data. The example of deleting out a record where 
someone is detained in possession of heroin by the police instead of an 
instance when they were found in possession of cannabis has already been 
discussed, however if one record includes the person’s area of residence and 
another does not, the geographical information should not be forgotten. 
Identification of overlaps 
Once the data from each contributing data source have been collected and 
cleaned, particularly in relation to the case definitions, a picture of the extent 
of drug use in a locality begins to be formed. The next stage is to fit the pieces 
of information together to identify the number of known users thus resulting in 
a multi-source enumeration. We have previously described the information 
that can be used to identify multiple occurrences, we will discuss the practical 
details of identifying these overlaps. 
The information from each source must be stored in the same format, not only 
in terms of the computer packages used, but also in the structure of the 
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database or the spreadsheet. Although possible, we discount the manual 
identification of overlaps as being impractical in anything but the smallest of 
prevalence studies. A typical spreadsheet storing information from a 
prevalence study could take the format shown in Figure 3.1 
Figure 3.1 Typical Spreadsheet Storing Data from a Capture-
recapture study. 
Source Ref. Fore 
Initial 
Sur 
Initial 
Date of 
Birth 
Sex Area Drugs 
Used 
Date 
1 1 A A 1/1/70 M N H 1/2/99 
1 2 B C 12/12/74 F E A, H 1/3/99 
In this example, the first record refers to a male with initials AA, born on the 
1st of January 1970, who lives in the north of the locality and was noted as 
using heroin on the 1st of February. The second record refers to a female who 
was noted as using amphetamines and heroin. They are indicated as  being in 
the same source (in this case Source 1), but have a unique reference number 
from within that source. Other auxiliary data may be stored, some of which 
would be particular to a specific source. For example, within a police source it 
may be useful to note if the person was detained for possession or supply, or 
within a treatment source it may be useful to have some indication about the 
length of time an individual has been using drugs. As long as the core fields in 
each record are stored in the same format and in the same column, it does not 
matter how much additional information is recorded within a spreadsheet. 
Once the data from each source is in the same format, with a different number 
indicating the source, there are several approaches to identifying overlaps. The 
method used could be subject to the individual preference of the researcher, 
however several issues should be noted. 
There are two main types of framework for identifying overlaps; deterministic 
and probabilistic. Within a deterministic framework, two records either match 
or do not match. Under a probabilistic framework, the probability that two 
records refer to the same individual is calculated, and this information is used 
to decide if it is a match or not. The former method is straightforward, 
however small inaccuracies within the data may affect the matching process. 
The later method may be too complicated to implement, therefore it is often a 
compromise between the two methods that is used. 
An understanding about the fields within a record is needed before matching 
commences. In some areas of Europe, either the forename or the surname of an 
individual may be practically any of the 26 letters of the alphabet. But some 
initials will be more common than others. Clearly the probability of someone 
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having the initials AB will more greater than the initials XV. The popularity of 
initials will vary throughout Europe, taking into account regional variations. 
Due to the age distribution of drug users, dates of birth corresponding to 
younger ages will be more common than those for example, in their sixties. 
This information on the relative probability of an individual having a given set 
of identifier information may be little more than common sense, however 
using it within a matching process is rarely systematic, rather it can be used 
subjectively in deciding what is or is not a match in some instances. 
One method of identifying overlaps would to merge the data from all sources 
into a single data file of a spreadsheet package then sort it by one (or more) of 
the identifiers. To minimise the effort in matching, it is prudent to sort first by 
the field which has the most permutations such as the date of birth. If a 
secondary sort is by surname initial then visual scanning of a file will quickly 
identify matches. It is also useful to have sorted by source number, particularly 
if there are three or more sources. This assists in categorising matches, e.g. by 
not differentiating between a ‘12’ match and a ‘21’ match which could both 
notify an individual as being in sources 1 and 2. Although a computerised 
matching procedure can be devised, perhaps using the macro facilities of a 
spreadsheet or its formulae, visual inspection and identification of overlaps 
may be the easiest way of accounting for inaccuracies in the data, e.g. by 
finding two records in which the initials are the same but the first two parts of 
the date of birth have been transposed. Although judgements about what will 
constitute a match in these cases can be subjective, it is important to be a 
systematic as possible in the process. 
Finally, when matching between data sources, care must be taken when 
allocating a match to each individuals. For example, it is sometime possible to 
note an overlap as an individual as being in source 1 and source 2, and still 
note that individual as being in source 1. One method would be to delete out 
the multiple occurrence so that only one record per unique individual remains 
within the data file. 
The result of this data collation process, whether done as described above or 
by using other methods, will be a large file which indicated the sources that 
each individual has been identified from. These data now need to be converted 
into a format to allow analyses by extracting the number of people identified as 
being solely in each of the sources and being in each combination of more than 
one source. This can be done either by counting the number of each different 
type of overlap, by using the statistical functions of the spreadsheet or by 
exporting the data to a statistical package. The sex, geographical area, the 
drugs used and the age (as calculated from the date of birth) should also be 
used to crosstabulate the data allowing the overlap pattern to be separately 
determined for males and females, younger and older drug users, opiate use / 
amphetamine users etc. 
The nature and quality of data will vary between sources, 
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therefore the data cleaning and data collation 
 may be a complex process 
 
Identifier information is subject to error, therefore the 
identification of overlaps is subject to error 
 
Errors in matching between sources may influence any 
prevalence estimates 
 
3.5 Data Analysis 
Once the size of the overlap between the different data sources have been 
found, then the data can be presented in the following manner, which is known 
as a contingency table. 
Table 3.1 Typical Contingency Table Summarising Data from a 
Capture-recapture Study 
  Source 1 
  Present Absent 
  Source 2 
  Present Absent Present Absent 
Source 3 Present 6 79 34 389 
 Absent 13 162 116 x 
In this table, we use data which were used to provide an estimate for the size 
of the opiate using population of Toulouse, see EMCDDA (1997b) for 
additional information on the three sources. Here six individuals were 
identified from all three sources, and 79 individuals were identified from 
Source 1 and Source 3, but not from Source 2. The hidden population is 
denoted as x, and it is this quantity that the capture-recapture method aims to 
estimate, and thus give an estimate of the total population size. The analysis of 
these particular data is presented as a worked example in an Appendix to this 
document. 
Statistical packages can be used to fit different models to the data and thus 
provide an estimate of the size of the hidden population. These different 
models will include the different relationships that may be between the three 
sources. If, however, the drug users identified from the three sources are 
substantially different from the drug users that have remained hidden, then 
there would be a three-way relationship between the sources. If this was the 
case,  then the analysis would not be able to offer a reliable estimate. 
To measure how close each model fits the data, a value known as the deviance 
can be calculated. Thus each estimate will have an associated deviance and the 
estimate which has the lowest deviance may be the most accurate. A 
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confidence interval can be attached to each estimate to give an indication about 
how accurate the estimate will be. 
As the analysis, and also the interpretation of the results, requires some 
statistical expertise, we leave an extended discussion to the next section. It is, 
however, recommended that those considering using capture-recapture 
methods to estimate the size of a drug using population should establish 
contact with those who have experience in using the methodology. 
The capture-recapture method may be used to obtain a 
prevalence estimate using data on the overlap between sources of 
information on drug misuse 
 
This statistical method is not straightforward therefore statistical 
assistance may be required within a prevalence estimation project 
 
There are methodological issues that need to be considered when 
using the method to estimate the prevalence of drug misuse 
 
3.6 Dissemination of results 
Although the capture-recapture method may appear complicated, there are 
several points that need to be considered when describing the research and 
writing up the results for dissemination. Many of the points raised below are 
common to any scientific study; the description should be transparent enough 
to allow others to re-analyse the data and to judge whether or not the 
conclusions made, particularly the prevalence estimates, are valid. Thus when 
writing about the research, the method should be more fully described, 
including a critical assessment of its applicability within the project.  
Within a report, each of the data sources should be described, along with 
summary statistics such as the age distribution and the sex breakdown. If 
geographical information from the various sources has been collected, then a 
description of the spatial distribution of the ‘known’ drug users can be 
illuminating. It may not be possible to completely describe how the case 
definitions of the project, in particular in relation to type and severity of drug 
use of the agency’s clients, are influenced by the choice of contributing 
sources, however a description of each source would be useful. 
A description of the matching process used to identify overlaps should be 
included, stating whether or not exact matching has been used or if a more 
subjective process has been followed, perhaps allowing for close matches to be 
identified as overlaps. Some indication about how accurate the process has 
been would aid the reader. 
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In order that other people may analyse the data themselves, the overlap pattern 
should be presented in a contingency table, and where possible contingency 
tables of the stratified data should also be produced. A table detailing the 
results of the analysis should also be presented, including some of the 
statistical output such as the deviance and the 95% confidence interval from 
each of the possible models. A reference should be given to the method used to 
calculate the confidence estimate. 
The resultant estimate should be placed in context with other information 
about the nature and extent of drug use within the locality within a discussion 
section. The estimate needs to be critically assessed, particularly in relation to 
the interactions that have been identified within the modelling process. 
The results from a prevalence research project should not only be disseminated 
to policy makers and service providers, but also back to the agencies from 
which the data were obtained. Not only should this been done out of courtesy, 
but showing the end result from the research project may help in gaining future 
access to similar data. 
It should be recognised that in producing a prevalence estimate, unwanted or 
inaccurate reporting in the media may follow. Indeed others with a vested 
interest in the results may seek to make political capital. Often there is little to 
compare a prevalence estimate with and what may appear to be a high 
prevalence of drug misuse may not be put into context or realistically 
compared with other areas. Unless comparable studies have been carried out 
over the same time period and using the same methodology and case 
definitions, there can be no valid direct comparisons made. That, however, 
may not stop people portraying the results as dramatic. 
Drug misuse prevalence estimates, particularly at the local level, 
may be open to interpretation 
 
Various people may have a vested interest in the estimates 
 
The prevalence estimates may be discussed, out of context, by 
sections of the media 
3.7 Summary 
We have detailed the process that is undertaken when using the capture-
recapture  methodology to estimate the size of a drug using population. There 
are various stages, from identifying data sources, collecting the data and 
identifying overlap cases through to analysing the data using statistical 
methods. Each stage is important, however the skills needed differ. Many of 
the stages rely on a clear and systematic approach to working with the data, 
however the analysis stage may require additional statistical knowledge. In the 
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next section we describe the statistical analysis in greater depth.  
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4 Statistical Analysis 
In this section we explore further the capture-recapture methodology, which 
can be used to estimate the size of hidden populations such as drug users. 
While it has been important in the preceding section to describe the method 
and the related assumptions in a manner accessible to those without a 
statistical background, it is also important that the methodology is discussed 
more rigorously. It is therefore assumed that the reader of this section is 
experienced in basic statistical analyses and has experience of using a 
statisitcal package such as GLIM, SPSS, SAS or BMDP. Those readers 
without a statistical background are advised to turn to the discussion in the 
following section. The following examples assume that three sources of data 
are used, however the analysis can easily be extended to four or more sources. 
4.1 Capture-recapture data 
Once the overlaps cases have been identified, using a method such as that 
described above, a contingency table can be constructed, as shown below. 
Table 4.1 Typical Contingency Table Summarising Data from a 
Capture-recapture Study 
  Source 1 
  Present Absent 
  Source 2 
  Present Absent Present Absent 
Source 3 Present a b e f 
 Absent c d g x 
In this table, the number of people who were identified from all three sources 
is denoted as a, those that were identified from Sources 1 and 2, but not 
Source 3 are denoted as c, and those that were only identified in Source 3 are 
denoted as f. The hidden population is denoted as x, and it is this quantity that 
the capture-recapture method aims to estimate, and thus give an estimate of the 
total population size. 
The number in each found in each source can be confirmed as follows: 
N1 = a + b + c + d 
N2 = a + c + e + g 
N3 = a + b + e + f 
Where N1 is the total of individuals identified from Source 1. The observed 
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population can also be found: 
    N  = a + b + c + d + e + f + g 
Thus N is the total number of drug users found from the multi-source 
enumeration.  
The data can alternatively be presented as a Venn Diagram, as shown below. 
Figure  4.1 Venn Diagram Summarising Data from a Capture-
recapture Study 
 
        d  c       g 
    Source 1       Source 2 
   b a e 
     f 
        Source 3   
x         Hidden Population 
 
4.2 Log-linear models 
The capture-recapture data, as summarised by a contingency table, can be 
analysed using a statistical package such as GLIM or SPSS. A log-linear 
regression model can be fitted to the data and this model can be used to 
provide an estimate of x, the size of the hidden population. An introduction to 
log-linear modelling, in particular its application in estimating the size of 
hidden populations is to be found in Bishop, Fienberg and Holland (1975). 
Different log-linear models can be fitted to the data to include interactions 
between data sources. For example, if drug users attending a treatment agency 
were more likely to have been admitted to hospital, then there would be 
positive interaction between these two sources. A decision as to whether such 
interactions are present can be made by examining a value known as the 
deviance (G2). This measures how closely the observed data agree with the 
model and is similar to the χ2 values commonly used to examine contingency 
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tables. As there are only seven cells in the contingency table instead of the 
eight that would usually be in such a table, it is only possible to fit interactions 
between two data sources (although three of these different interactions can be 
fitted), along with fitting pairs of interactions. 
It is not possible to include a simultaneous interaction between all three data 
sources therefore it is a necessary within the analysis to assume that this ‘three-
way’ interaction is zero. This assumption may not be valid, and the validity 
will be related to the size of the deviance when fitting the best model to the 
data. If this deviance value is large, even after including all possible 
interactions, then the resultant estimate may be biased. Once an estimate has 
been obtained, then a confidence interval can be produced. Several methods 
can be used to produce this confidence interval, depending on the statistical 
package that has been used to analyse the data. 
4.3 Model Selection 
Hook and Regal (1997) discuss the validity of methods for model selection 
and weighting for model uncertainty in capture-recapture estimation. In 
addition to describing the Akaike Information Criterion (AIC), which can be 
used to assess whether interactions should be included in models and therefore 
can be of use in choosing the ‘best’ model (Akaike, 1985), they discuss the 
Bayesian Information Criterion (BIC) which can take two different forms, the 
original as proposed by Schwarz (1978), the other an alteration proposed by 
Draper (1995). Hook and Regal denote these as SIC and DIC respectively. The 
formulae for these criteria are as follows: 
    
   AIC =  G2 - 2(df), 
   SIC =  G2 - (ln Nobs)(df), 
   DIC = G2 - (ln (Nobs/2π))(df), 
 
where G2 is the deviance and df is number of degrees of freedom associated 
with the model, Nobs is the ‘known’ population of opiate users and ln denotes 
the natural logarithm function. When using any of these criteria the model with 
the lowest value of the criterion would be the favoured one. 
Hook and Regal go on to discuss the use of the weighted Bayesian Information 
Criteria, in which both the SIC and the DIC can be used to obtain a weighted 
average of the different estimates from the three-sample capture-recapture 
method; these weighted averages can also be applied to the upper and lower 
values of the 95% confidence intervals associated with the eight estimates. 
These weighted estimates can be considered as ‘Bayesian’ as they combine an 
estimate with a measure of how likely it is, to produce the weighted estimate. 
Hook (personal communication) recommends using all possible three-sample 
estimates to construct the weighted estimate, including the model which 
includes all two-way interactions between the three data sources and has an 
associated deviance of zero. There does, however, appear be to some 
justification for not including this ‘saturated model’. Similarly, it may be 
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questionable to include estimates in which the associated deviance suggests 
that the model clearly does not fit the data. 
The selection of the models used to describe the overlap pattern and to produce 
an estimate of the size of the hidden population is, on one level, intrinsically 
linked with the discussions about case definitions and the data sources that are 
employed. On another level the concept of parsimony is also important such 
that simple models without complex interactions may be preferable. It is not 
always possible to fit certain models to the stratified data due to zero values in 
some cells. Related to the problem of structural zeros, where a mechanism 
exists which ensures that no overlap can occur between certain sources is the 
problem of artificial overlaps where inclusion in one source will automatically 
mean inclusion in another.  
An additional benefit of the three-sample capture-recapture method, as 
opposed to the two-samples, is that a specific interaction can be included in the 
model, even when a criterion such as the AIC does not make the suggestion. In 
many instances, interactions can be included which are consistent with what 
professionals in the field would expect, i.e. ‘medical’ sources being dependent 
on each other but independent of a ‘legal’ source. Without returning to the 
discussion the case definitions, this is sensible when you consider the 
differences between those who have ‘medical’ problems due to drugs and 
those who only have legal problems.  
The debate between including interactions because they seem sensible, and 
being led by statistics such as the change in deviance or the AIC, is made more 
interesting because log-linear modelling, which capture-recapture modelling 
essentially consist of, is the preferred method of examining categorical data, 
and thus discovering relationships between sources. It is also possible that the 
sample sizes, in this case the data from the sources may not be large enough to 
show significant interactions, even when they are present. If these interactions 
are thought to be present between data sources then they should perhaps be 
included. 
4.4 Confidence Intervals 
The estimates obtained from the application of a method such as capture-
recapture need to be assessed in conjunction with the statistical uncertainty 
that is inherent in any estimate. Those that successfully undertake capture-
recapture studies are in some way fortunate in that the estimates produced can 
usually only be compared with ball-park estimates derived by those working in 
the field. The number of ‘current’ drug users within a city will be variable and, 
as trends in drug use can fluctuate, the best any prevalence study can hope for 
when using retrospective data is a historical estimate of drug use; this usually 
is still of relevance to policy makers at the present time. Additionally, any 
statistical estimate needs to be interpreted with caution for the reasons detailed 
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below. 
The estimate produced from a capture-recapture project is the end point of a 
process in which error can be introduced at several stages. Mistakes can be 
made during the collation of an individual data source; identifiers such as the 
date of birth can be recorded erroneously either by mistake or because falsified 
information has been recorded, particularly in a low-threshold agency. The 
matching process is not always guaranteed to correctly identify all matches, or 
eliminate any possible false matches. It is only once a contingency table has 
been produced that the statistical modelling can commence, and even then, the 
relevance of the confidence interval depends on how accurately the model 
portrays the relationships between the data sources. 
Various methods for producing a confidence interval can be used, however a 
method favoured by Cormack (1992) and by Regal and Hook (1984) which 
recognises that the estimate for the hidden population is derived from an 
asymmetric distribution has commonly been used. Thus the possible problem 
of producing confidence intervals, in which the lower bound of the total drug 
using population is less than that which has been identified from the multi-
source enumeration, does not arise. Sometimes, however, the upper limits of 
the confidence intervals reported are simply not feasible, and these usually 
occur when the model has included more than one interaction. That is not to 
say that a preferred estimate should be chosen because of its small confidence 
interval.  
The three-sample capture-recapture analysis can be carried out on a range of 
statistical software, often with the aid of pre-written macros or subroutines. 
While the point estimates derived are usually exactly similar, the methods for 
obtaining confidence intervals sometimes differ therefore there needs to be a 
consensus about which packages are of most use. We can now demonstrate the 
use of two different packages, GLIM and SPSS in analysing capture-recapture 
data. 
4.5 Analyses using GLIM 
This section describes how the GLIM statistical package (Francis et al, 1994) 
can be used within the analyses of data from multiple sources within a capture-
recapture analyses.  The GLIM package (GLIM4) was developed by the Royal 
Statistical Society (UK). It is described as 'The Statistical System for 
Generalized Linear Interaction Modelling' and can be used in many types of 
statistical analysis of data, including model fitting. More information about the 
package can be found at the NAG website http://www.nag.co.uk It should be 
noted however that the package operates on PCs through an interface to MS 
DOS, and both the installation and operation of the package are less 
straightforward than traditional Windows based packages. 
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Capture-recapture data 
To analyse the data using GLIM, we assume that the data has been converted 
into the following format. 
Table 4.2 Data Table Summarising Data from a Capture-recapture 
Study 
Source 1 Source 2 Source 3 Count 
1 1 1 a 
0 1 1 e 
1 0 1 b 
0 0 1 f 
1 1 0 c 
0 1 0 g 
1 0 0 d 
0 0 0 x 
The hidden population in all of the above is denoted as x, and it is this quantity 
that the capture-recapture method aims to estimate, and thus give an estimate 
of the total population size. Within the data table, the presence in each source 
is denoted by 1, and absence by 0. 
N1 = a + b + c + d 
N2 = a + c + e + g 
N3 = a + b + e + f 
The observed population can also be found: 
    N  = a + b + c + d + e + f + g 
Analyses 
The three sources are known as factors and the 7 counts (and the missing 
value) are known as the response variable. Annotated output from a GLIM 
session is presented within this document. Once a GLIM session has started, 
commands are inputted and they appear in the annotated output preceded by 
[i]. Commands in GLIM are always preceded  by the dollar sign $, and a 
command line is terminated by $. Only the first four letters of a command are 
recognised, therefore abbreviations can be used. To repeat a command the ‘:’ 
can be used. The first command is to set the standard length of the data, using 
the command  
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$units 8$
Thus when any data are entered, GLIM expects 8 values. The series of counts 
can then be entered, using the $data r$ and $read commands. To input 
the data line by line, we can omit the final $ to get prompted for data by 
GLIM. Thus the seven counts will be stored in a variable r. By convention the 
missing value is set to be zero. 
We need to input the factors (presence or absence from each source) and other 
information about the modelling process that will be undertaken. By 
convention, the factors are named p1, p2 and p3, and a weighting variable w is 
assigned. This weighting variable lets GLIM know that the 8th value of r is 
missing. To assist in fitting different models, it is useful to assign names to the 
different interaction terms that can be fitted. By convention, an interaction 
between source 1 and source 3 is named i13. To shorten these names, the 
interaction between source 1 and source 2 is named i1 instead of i12 and the 
other interaction term is named i2. This is done by multiplying the factors 
together, using the commands such as 
$calc i1=p1*p2$
Some other information is needed for GLIM to fit different models; an 
indication of which variable is the response variable, what distribution the 
values of the count variable will take (usually Poisson), and what weight 
should be used 
$yvar r$
$err p$
$weight w$ 
Fitting different  models is done using the $fit$ command. For example 
$fit p1+p2+p3$
will fit the basic model with no interactions. GLIM responds with two values, 
the scaled deviance and the residual df. The scaled deviance, known as G2, is 
comparable to values compared to a χ2 when examining contingency tables. G2 
is a measure of how well the model fits the data, and thus we wish it be low. 
There are 3 degrees of freedom (df) when fitting this basic model. 
Different interactions terms can be added: 
$fit +i1$
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or removed 
$fit –i1$
such that 
$fit p1+p2+p3$
followed by  
$fit +i1$
would fit the model with an interaction between source 1 and source 2. 
Alternatively this can be done directly by  
$fit p1+p2+p3+i1$
The benefit of adding and removing the interaction terms is that GLIM will 
give the change in deviance as well. As a check to see what model has actually 
been fitted by displaying the model. 
$d m$
would display the model.  To see what GLIM has estimated the missing value 
to be there are two options. One is to display a table which presents the 
observed and fitted values, along with the residuals: 
$d r$
The other would be to look at the 8th fitted value: 
$look 8 %fv$
It should be noted that this is the estimated size of the hidden population, the 
known population (the sum of the other seven cells) must be added to get the 
total population size estimate. When there are three data sources, there are 
essentially only eight models that can be fitted. The independence model with 
not interactions, the three models that have one interaction, the three models 
that have two interactions, and the model that has all three interactions, which 
is known as the saturated model. As the saturated model uses all available 
data, the degrees of freedom should be zero, as will be the deviance. 
To examine the significance of each of the interactions that are included in the 
model, the GLIM can display the estimates: 
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 $d e$
It is quite useful to know the size of the interaction and the standard errors 
associated with them, particularly when the sample size is small or when a lot 
of interaction terms are included in a model. 
So far, only point estimates (along with a measure of how good the associated 
model is) have been obtained. It is also necessary to obtain confidence 
intervals. Although Bishop, Fienbierg and Holland (1975) suggest a method 
for obtaining symmetrical confidence intervals, the approach, independently 
proposed by Cormack (1989) and Regal and Hook (1984) is preferable. Both 
method aim to find a value, sufficiently far from the point estimate to increase 
the deviance by 3.84 (the 5% significance point of the χ2 distribution). Two 
further point estimates, both known as weighted Bayesian estimates, can be 
produced, along with confidence intervals. In short, these estimates use either 
the DIC or SIC, along the corresponding estimates, to obtain a weighted 
estimate.  
Finally, the command to end a GLIM session is $stop$ and two files should 
have been produced glim.jou, which records the commands that have been 
entered in the preceding session, and glim.log which additionally records the 
output. As the next session of GLIM would overwrite these files, it may be 
useful to rename them if they are to be needed again. 
Macros can be written for GLIM, and the analysis of capture-recapture data 
can be simplified by using a macro, however it is useful to have a basic 
knowledge of some of the commands used in GLIM. For example, most of the 
commands used in describing the analysis, apart from setting the unit length 
and entering the count data, can be undertaken by running a macro. A macro 
can also be created to obtain and output the estimate for the size of the hidden 
population for each possible model. Such a macro can also easily calculate the 
two sample estimates (e.g. only using source 1 and source 2 and looking at the 
traditional two-sample estimate). Following on from Hook and Regal (1997), 
criteria for selecting the ‘best’ model such as the AIC, DIC or SIC can also be 
calculated using a macro and the method for obtaining a 95% confidence 
interval proposed by Cormack can also be implemented using a macro. 
 
4.6 Analyses using SPSS 
This section describes how the SPSS statistical package can be used within the 
analyses of data from multiple sources within a capture-recapture analyses. It 
may be easier to analysis capture-recapture data using the GLIM software, 
partly because these packages are more suited to the type of analysis. A 
description of the analyses using SPSS is presented more for those who are 
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acquainted with this statistical package or for those who only have access to 
this package. 
SPSS is a powerful software package for data management and analysis. 
Various versions will be in use on different computer systems, however the 
analyses described in this report requires the equivalent of Version 6.1 for 
Microsoft Windows or a more recent version. The examples presented within 
this report were obtained by using Version 7.5 for Microsoft windows using 
the General Loglinear analysis commands which are contained within the 
Advanced Statistics add-on enhancement to the base system. Further 
information on the SPSS package can be found at http://www.spss.com  
The more recent versions of SPSS make use of drop down menus as opposed 
to syntax commands that some more experienced SPSS users may be more 
familiar with. The following example describes the use of the menus, however 
the syntax is also presented. 
Capture-recapture data 
We have previously shown how the data can be presented visually within a 
Venn diagram. We now need to show how this data can be converted into a 
format required by SPSS.  
Table 4.3 Data Table for Use with SPSS 
Source 1 Source 2 Source 3 Count 
1 1 1 a 
2 1 1 e 
1 2 1 b 
2 2 1 f 
1 1 2 c 
2 1 2 g 
1 2 2 d 
2 2 2 x 
The hidden population in all of the above is denoted as x, and it is this quantity 
that the capture-recapture method aims to estimate, and thus give an estimate 
of the total population size. Within the data table, the presence in each source 
is denoted by 1, and absence by 2. It should be noted that this terminology 
differs from the conventional ‘1 for presence and 0 for absence’ which is used 
when analysing the data using GLIM. This is to enable the analyses in SPSS. 
The number in each found in each source can be confirmed as follows: 
N1 = a + b + c + d 
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N2 = a + c + e + g 
N3 = a + b + e + f 
The observed population can also be found: 
    N  = a + b + c + d + e + f + g 
Analyses 
To analyse this type of data, it must be in the format of a data table as 
described above.  The three sources are known as factors and the 7 counts (and 
the missing value) are known as the response variable. Annotated output from 
an SPSS session is presented as within this document. 
The first step is to enter the data into SPSS. The data presented here is the 
same as that presented in the GLIM analyses to enable a more direct 
comparison. The data can be entered in the following format: 
Table 4.4 SPSS Spreadsheet 
p1 p2 p3 w r 
1 1 1 1 6 
2 1 1 1 34 
1 2 1 1 79 
2 2 1 1 389 
1 1 2 1 13 
2 1 2 1 116 
1 2 2 1 162 
2 2 2 0 0 
It may be convenient to define each variable p1, p2, p3, w and r as type 
‘Numeric’ with 0 decimal places. We show here the data that are analysed as a 
worked example in an Appendix. 
The variable which stores the seven counts, r, needs to be identified as such. 
This can be done by using the  
 Data 
  Weight Cases… 
   Weight cases by 
commands, where the ‘Frequency Variable’ is selected to be r. 
In order to find the best fitting model, a variety of approaches can be taken, 
however one of the most convenient would be to fit the model with all 2-way 
interactions and use the back stepping method to test which interactions can be 
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removed from the model (Smit, Brunenberg and Van der Heijden, 1996). 
To do this, the  
Statistics 
Loglinear 
Model Selection 
commands are used. The three factors; p1, p2 and p3, are entered into the 
Factor(s) box and the range of these factors are defined to have the minimum 
value 1 and maximum value 2. The Cell Weights are set to be w. The Model…
window can be used to include all 2-way interactions (p1*p2, p2*p3 and 
p1*p3) as the model which the backward elimination starts at. Using this 
method should result in the most parsimonious model which SPSS then 
displays. 
To then go on to find the estimate of the hidden population size, the parameter 
estimates for that model must be obtained. This is done by using the  
Statistics 
Loglinear 
General 
commands. Here again p1, p2 and p3 are entered into the Factor(s) box and w 
is entered into the Cell Structure box. The Distribution of Cell Counts should be 
set to be Poisson and the Model… window should be used to enter the specific 
model which SPSS has suggested is the most parsimonious (or for that matter 
any other model for which an estimate is required). Use the Options… window 
to specify that the Estimates are required. The plots that SPSS suggests are not 
required.  
The estimate of the hidden population size can be calculated as the exponential 
of the value of the constant parameter. An asymptotic 95% confidence interval 
for the size of the hidden population can be obtained by calculating the 
exponentials of the vales SPSS gives as a  confidence interval. 
Instead of using the menu-driven commands, the following SPSS syntax can 
be used, after the data has been entered in the above format. 
Weight by r. 
Hiloglinear 
 p1(1,2) p2(1,2) p3(1,2) 
 /cweight w 
 /method backward 
 /print freq resid 
 /design p1*p2 p1*p3 p2*p3. 
Genlog 
 p1 p2 p3 
 /cstructure = w 
 /model = Poisson 
 /print estim 
 /plot none 
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 /design p1 p2 p3 p1*p3. (or whatever the suggested model is) 
The annotated output from such an analyses is to be found at the end of this 
report. 
Although SPSS can be used to fit various models to capture-recapture data, 
and thus provide an estimate for the size of a hidden population, it does not 
appear capable of calculating non-symmetric confidence intervals based on the 
likelihood approach such as that proposed by Regal and Hook (1984) or 
Cormack (1992). 
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5 Discussion and Conclusions 
In the preceding sections we have described how data on drug misuse can be 
collected from a range of sources and can then be used to provide an estimate 
of the prevalence of drug misuse using capture-recapture methods. In this 
section we provide a methodological discussion, focussing on aspects of the 
prevalence estimation exercise that need to be addressed when the reliability 
and validity of an estimate is considered. 
5.1 Methodological issues 
The capture-recapture methodology was developed to estimate the size of 
animal populations and has been used in epidemiological studies to estimate 
the size of under-reporting in disease registers. A review of the theoretical 
development of the methodology is to be found in a related publication, 
however a discussion of the methodological issues, particularly in relation to 
estimating the size of drug using populations is now warranted. 
In studies which aim to estimate the size of an animal population (for example 
see Seber, 1982), there are a series of assumptions or conditions that must be 
true for the estimates to be valid. Most of the assumptions translate into our 
epidemiological application, for example: 
• The population is closed; there is no movement into or out of the 
population in the period that is being studied; 
• Those that are present in more than one source - the overlap cases - are 
identified as such. 
• Being present in one source does not effect the probability of being in 
another source; 
We can now look at these assumptions in closer detail and discuss their 
validity with respect to drug misuse prevalence estimation. 
For the first assumption to be true, then the population of drug users must 
remain constant over the study period and nobody starts or ceases to fall under 
the remit of the study. There are two main ways that this can be violated, either 
by individuals moving away from or into the study area, or by people either 
ceasing or starting to use drugs. In some areas, the movement in and out of a 
city by drug users can cast doubts on the validity of the assumption, for 
example by drug ‘tourists’ visiting areas where drugs are more available. This 
problem can be partially addressed by stipulating in the study definition that 
persons must be resident in the city, or have been resident for some time prior 
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to inclusion in the study. In other areas, the small amount of migration of drug 
users would do little to affect the analysis. 
The second problem with the ‘closed population’ assumption is often harder to 
address. It would be unrealistic to assume that people would not begin using 
drugs during the study period, and clearly the provision of drug treatment 
services may indeed help people to stop using drugs. The increased mortality 
of drug users should not be ignored either. One approach to making the 
assumption more valid would be to shorten the study period. The associated 
cost may however be to reduce the amount of available data on drug users such 
that it is not possible to fit the most realistic model. This may result in either a 
totally unrealistic estimate or a plausible, but false, one. 
The second assumption requires that the identification of overlaps is not 
subject to error. As in other areas, there exists the possibility of false positives 
and false negatives. Due to errors in the recording of data, and because full 
identifier information is seldom available with which to match, people may be 
wrongly identified as being in more than one source, or more likely that an 
overlap case is not identified as such. 
The third assumption is often harder to describe as it relates to more than one 
problem. The first problem is that the study population is heterogeneous; drug 
users, for whatever reason, are not all equally as likely to be present in a 
particular source. The second problem is that those present in one source may 
be more, or less, likely, to be in another. Drug users, and their lifestyles, are 
diverse, and this diversity can be reflected in many ways. Steps can be taken to 
make the first part of the assumption valid. It may perhaps be possible that 
male drug users have a different probability of being arrested than female drug 
users, or that younger drug users are less likely to contact services than older 
drug users. This variability, if it exists, should therefore be accounted for. One 
method would be to stratify the population, perhaps by age or sex, to give a 
more homogenous population on which to undertake the analysis, however the 
comment above about reducing the amount of data on which to perform the 
analysis is equally valid.  
There is a related problem in that spatial variation may also exist. This 
problem may not be so pertinent when an entirely urban location is being 
studied, but if there are areas within the study location where perhaps access to 
drug treatment services are reduced, or the police may be less likely to detain 
drug users then a model fitted to the data for the entire city may not be valid 
for that area. Again a solution may be to stratify the data by geographical area. 
There also exists the problem such that, although it may be possible to stratify 
the population by age or sex, a more worrying source of heterogeneity may be 
the severity of a persons drug problem. Clearly those with a bigger drug 
problem would be more likely to contact services, therefore a prevalence study 
which only used sources of data which cater for more problematic drug user 
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should result in an estimate of the total number of problematic drug users in 
that area. However, other drug users may be better classified as having only a 
legal problem with drug use, either due to laws restricting the possession or the 
supply of drugs, or the need to commit crime to finance their drug use. These 
drug users may be unlikely to contact medical services and if the contributing 
sources therefore include both problematic and non-problematic drug users, 
the ‘equal probability’ assumption may be violated. 
The second part of the ‘equal probability’ assumption is also difficult to 
resolve. An example of how this assumption may be violated would be a 
system where those who have been detained for a drug offence by the police 
would be required to attend at a drug treatment service, or perhaps because 
someone is being prescribed methadone from one treatment source then they 
would not be attending the local needle exchange.  
The effect of this, and the other violations of the assumptions is often unclear. 
Methodological studies can begin to explore the possible effects on prevalence 
estimates any violation of the assumptions may have, unfortunately the 
dynamics of drug misuse is often far to complex to be completely understood. 
While the violation of one assumption may result in an underestimate, another 
violation may result in an overestimate. It cannot however be assumed that 
these would cancel each other out. 
It is often not until the analysis stage that the effect of any violation of the 
assumptions may be recognised, perhaps by the inability to obtain a simple 
model that fits the data. Even when a model appears to accurately describe the 
overlap data, it cannot be guaranteed that a violation of the assumptions has 
rendered the estimate unreliable. It is because of this that some regard the 
capture-recapture method itself as being unreliable and would not recommend 
its use in prevalence estimation (Papoz et al., 1996). Others take a more 
pragmatic approach, preferring to undertake the analysis and then to judge the 
estimate’s reliability, particularly in relation to the assumptions and the model 
that has been fitted to the data (IWGDMF, 1995; Hook and Regal 1995). There 
is no right or wrong answer, the estimate produced is just that; an estimate. 
Whether or not that is of use in determining how many people use drugs in a 
specific locality is a decision that can only be made after the analysis is 
completed.  
5.2 Refinements 
There are several refinements to the basic analyses that can be made, lessening 
the effect possible violations of assumptions and thus making the resultant 
estimate more valid. While one approach would be to increase the number of 
data sources, perhaps by collecting additional data, it may be more sensible to 
effectively decrease the number of sources that are used within the analyses. 
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If many sources are available, it may be that some of them have a similar remit 
or that relationships exist between them to justify merging them together. Thus 
a capture-recapture recapture study which initially had four or five sources 
may benefit from merging similar sources together and re-analysing the data. 
Another approach may be to examine combinations of sources selected from 
the total number of available sources. For example, if five sources were 
initially available, systematically removing one or two sources and re-
analysing the data may uncover relationships between the sources and aid the 
decision as to what constitutes a valid estimate. An extreme example of this 
would be to perform two-sample analyses on subsets of the data. It would be 
unlikely if any of these estimates in themselves would be reliable, however the 
combination of estimates may then give an insight as to what the true 
population size may be. 
There is a related method, known as the truncated Poisson model which can be 
used to obtain a prevalence size estimate from one source of data. It requires 
information on the number of times an individual has been in contact with that 
particular source, and therefore may be more suited to some sources rather 
than others. It works on the principle that if the number of people attending 
once, twice, three times and so on is known, then this information can be used 
to estimate how many people have attended zero times, i.e. the hidden 
population. In a similar manner to the three-sample capture-recapture method 
assuming a log-linear model to describe the contact pattern between sources, 
the truncated Poisson model would model the number of contacts within a 
single source as a Poisson distribution. As no information can be drawn about 
the number of zero contacts, the Poisson distribution is truncated. A fuller 
description of this methodology is to be found in the report from the previous 
EMCDDA project (EMCDDA, 1997b), however it should be noted that the 
estimates are again subject to some of the assumptions present in the capture-
recapture analysis: the closed population assumption, the homogeneous 
population assumption and the constant probability of being observed more 
than once assumption, in this case over time.  
Other refinements to the basic model may theoretically possible, for example 
by implicitly modelling an open population, however such models would 
require more data than the closed population capture-recapture method. Thus 
this method has rarely been used within Europe.  
5.3 Conclusions 
We have described above some of the more pertinent issues that need to be 
considered when carrying out a local prevalence study using the capture-
recapture method. The section has been drawn from the authors experience in 
applying the methodology in a variety of settings, however it would be over-
optimistic to assume that all possible problems that a prevalence study may 
encounter have been described. Local variations in the nature and extent of 
drug misuse, along with factors such as the availability of data may serve to 
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present additional problems that can only be addressed at the local level. 
The estimation of the prevalence of drug misuse at the local level should be 
put into context. In some instances the availability of data may result in the 
costs of initiating a study becoming prohibitive, particularly when the success 
of a study may be limited because of the scarcity of data. In other areas, data 
on drug misuse is already being collated, and a capture-recapture study may be 
an inexpensive way of interpreting the data and giving an estimate of the total 
population size. Thus the costs of a prevalence study need to be weighed 
against the possible benefits, particularly in relation to other the different 
methods that can be used. The fact that a capture-recapture study can use 
existing data may mean that it can be one of the quickest methods of providing 
a prevalence estimate, particularly if it is incorporated into a monitoring 
system. Although repeat capture-recapture studies have been rare, there 
appears no reason why they cannot be systematically applied, perhaps in 
conjunction with a monitoring system to provide information on trends. 
Thought must also be given as to the uses of prevalence estimates and the 
proper interpretation. As an initial step within a capture-recapture study is to 
find the number of known users, the ratio of known to unknown users can be 
obtained and considered. Care must be taken however in making direct 
comparisons between the known population, the estimated population and the 
number of people contacting treatment services. There may be many valid 
reasons why only a proportion of the total population of drug users are in 
contact with services. Some drug misusers may not wish to seek treatment for 
their drug problems, indeed they may not even perceive themselves to have a 
problem. Other drug misusers may feel that their problems may not be catered 
for by existing services. 
Finally, care must also be taken to distinguish what the prevalence estimate 
does not encompass. Capture-recapture estimates typically refer to drug misuse 
at the more problematic end of the drug using spectrum, and can often 
disregard the use of particular drugs such as amphetamines. When using any 
prevalence estimate, it must be stressed that other drug problems may exist, 
and just because one type of drug problem has been enumerated, it does not 
mean that others are irrelevant. This warning may be particularly pertinent 
when using the results of a capture-recapture study to plan services. There may 
be a vicious circle in that data from treatment agencies which mainly provide 
treatment for opiate use are used to show that opiate use is prevalent in that 
area and therefore more opiate misuse based services should be provided, 
perhaps at the expense of providing services for other forms of drug misuse. 
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Appendix I Typical GLIM session which provides an estimate of the size of a 
hidden population using data from 3 sources.
[o] GLIM 4, update 8 for IBM etc. 80386 PC / DOS on 27-Jun-1998 at 14:38:07
[o] (copyright) 1992 Royal Statistical Society, London
[o]
[i] ? $units 8$  Sets the size of the data columns. 8 cells in the contingency table. 
[i] ? $data r$ Input the data from the contingency table 
[i] ? $read
[i] $REA? 6
[i] $REA? 34
[i] $REA? 79
[i] $REA? 389
[i] $REA? 13
[i] $REA? 116
[i] $REA? 162
[i] $REA? 0  This is the missing cell which we aim to estimate. It should be set to zero. 
[i] ? $data p1$ This factor describes presence or absence from source 1 
[i] ? $read
[i] $REA? 1
[i] $REA? 0
[i] $REA? 1
[i] $REA? 0
[i] $REA? 1
[i] $REA? 0
[i] $REA? 1
[i] $REA? 0
[i] ? $data p2$ This factor describes presence or absence from source 2
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[i] ? $read
[i] $REA? 1
[i] $REA? 1
[i] $REA? 0
[i] $REA? 0
[i] $REA? 1
[i] $REA? 1
[i] $REA? 0
[i] $REA? 0
[i] ? $data p3$ This factor describes presence or absence from source 3
[i] ? $read
[i] $REA? 1
[i] $REA? 1
[i] $REA? 1
[i] $REA? 1
[i] $REA? 0
[i] $REA? 0
[i] $REA? 0
[i] $REA? 0
[i] ? $calc i1=p1*p2$ Calculates the interaction terms 
[i] ? $calc i2=p2*p3$
[i] ? $calc i13=p1*p3$
[i] ? $data w$ This variable is a weight used to denote which is the missing cell 
[i] ? $read
[i] $REA? 1
[i] $REA? 1
[i] $REA? 1
[i] $REA? 1
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[i] $REA? 1
[i] $REA? 1
[i] $REA? 1
[i] $REA? 0
[i] ? $look p1 p2 p3 w r$ Just to check the structure of the variables
[o] P1 P2 P3 W R
[o] 1 1.000 1.000 1.000 1.000 6.00
[o] 2 0.000 1.000 1.000 1.000 34.00
[o] 3 1.000 0.000 1.000 1.000 79.00
[o] 4 0.000 0.000 1.000 1.000 389.00
[o] 5 1.000 1.000 0.000 1.000 13.00
[o] 6 0.000 1.000 0.000 1.000 116.00
[o] 7 1.000 0.000 0.000 1.000 162.00
[o] 8 0.000 0.000 0.000 0.000 0.00
[i] ? $yvar r$ Tells GLIM that r is the response variable in the regression model 
[i] ? $err p$ Tells GLIM that the error structure is Poisson 
 
[i] ? $weight w$ Tells GLIM to ignore the cells that we have weighted out when fitting models 
[i] ? $fit p1+p2+p3$ This fits the basic model with no interactions between the data sources 
[o] scaled deviance = 6.5681 at cycle 3
[o] residual df = 3 from 7 observations
[o]
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The output here presents the deviance (G2) value, which can be compared with a χ2 
distribution with 3 degrees of freedom. 
  
  [i] ? $look 8 %fv$ Here we can check the estimated value (the 8th fitted value)
[o] %FV
[o] 8 1009. The estimated hidden population would be 1,009 if this model was the best fitting 
[i] ? $d r$
[o] unit observed fitted residual Alternatively we can display the residual values 
[o] 1 6 6.827 -0.317
[o] 2 34 40.653 -1.043
[o] 3 79 66.219 1.571
[o] 4 389 394.301 -0.267
[o] 5 13 17.474 -1.070
[o] 6 116 104.046 1.172
[o] 7 162 169.480 -0.575
[o] (8) 0 1009.168 0.000 Again this shows the size of the hidden population 
[o] 
 
[i] ? $fit +i1$ Here we include the interaction between sources 1 and 2
[o] scaled deviance = 4.7612 (change = -1.807) at cycle 3
[o] residual df = 2 (change = -1 ) from 7 observations
We can see how including the interaction slightly improves the fit 
[i] ? $fit -i1$ We can take this interaction back out again to return to the basic model 
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[o] scaled deviance = 6.5681 (change = +1.807) at cycle 3
[o] residual df = 3 (change = +1 ) from 7 observations
[o]
[i] ? $fit p1+p2+p3+i1$ Alternatively this command could have been used to go direct to the model with the 
interaction 
[o] scaled deviance = 4.7612 at cycle 3
[o] residual df = 2 from 7 observations
[o]
We can include / take out the different interactions as follows. We have only displayed the size of the estimate for the model that 
we previously know is the best fitting. 
[i] ? $fit p1+p2+p3$
[o] scaled deviance = 6.5681 at cycle 3
[o] residual df = 3 from 7 observations
[o]
[i] ? $fit +i2$
[o] scaled deviance = 3.9020 (change = -2.666) at cycle 3
[o] residual df = 2 (change = -1 ) from 7 observations
[o]
[i] ? $fit -i2$
[o] scaled deviance = 6.5681 (change = +2.666) at cycle 3
[o] residual df = 3 (change = +1 ) from 7 observations
[o]
[i] ? $fit +i13$
[o] scaled deviance = 0.13241 (change = -6.436) at cycle 3
[o] residual df = 2 (change = -1 ) from 7 observations
[o]
[i] ? $fit -i13$
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[o] scaled deviance = 6.5681 (change = +6.436) at cycle 3
[o] residual df = 3 (change = +1 ) from 7 observations
[o]
[i] ? $fit +i1+i2$
[o] scaled deviance = 0.69978 (change = -5.868) at cycle 3
[o] residual df = 1 (change = -2 ) from 7 observations
[o]
[i] ? $fit -i2+i13$
[o] scaled deviance = 0.011611 (change = -0.6882) at cycle 3
[o] residual df = 1 (change = 0 ) from 7 observations
[o]
[i] ? $fit -i1+i2$
[o] scaled deviance = 0.096012 (change = +0.08440) at cycle 3
[o] residual df = 1 (change = 0 ) from 7 observations
[o]
[i] ? $fit p1+p2+p3$
[o] scaled deviance = 6.5681 at cycle 3
[o] residual df = 3 from 7 observations
[o]
[i] ? $fit p1+p2+p3+i13$
[o] scaled deviance = 0.13241 at cycle 3
[o] residual df = 2 from 7 observations
[o]
[i] ? $look 8 %fv$ As this is the model that is judged to be the best fitting we again look at the estimate 
[o] %FV
[o] 8 1379.
[i] ? $d r$
[o] unit observed fitted residual
[o] 1 6 6.596 -0.232
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[o] 2 34 32.824 0.205
[o] 3 79 78.404 0.067
[o] 4 389 390.176 -0.060
[o] 5 13 13.580 -0.157
[o] 6 116 116.000 0.000
[o] 7 162 161.420 0.046
[o] (8) 0 1378.868 0.000
[o]
[i] ? $stop We finish the GLIM session. 
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Appendix II Typical SPSS session which provides an estimate of the size of a 
hidden population using data from 3 sources. 
* * * * * * * * H I E R A R C H I C A L L O G L I N E A R * * * * * * * *
DATA Information Information about the 
analysis 
8 unweighted cases accepted.
0 cases rejected because of out-of-range factor values.
0 cases rejected because of missing data.
799 weighted cases will be used in the analysis.
FACTOR Information
Factor Level Label
P1 2
P2 2
P3 2
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
* * * * * * * * H I E R A R C H I C A L L O G L I N E A R * * * * * * * *
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Backward Elimination (p = .050) for DESIGN 1 with generating class The model with all
two-way interactions 
P1*P2 is fitted
P1*P3
P2*P3
Likelihood ratio chi square = .20682 DF = 1 P = .649
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
If Deleted Simple Effect is DF L.R. Chisq Change Prob Iter
P1*P2 1 .000 1.0000 20
Step 1
The best model has generating class The interaction p1*p2
is removed and the  
P1*P3 change in χ2  is found
P2*P3
Likelihood ratio chi square = .10429 DF = 2 P = .949
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
If Deleted Simple Effect is DF L.R. Chisq Change Prob Iter
P1*P3 1 3.798 .0513 10
P2*P3 1 .029 .8644 12
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Step 2 Other interactions are 
examined 
The best model has generating class
P1*P3
P2
Likelihood ratio chi square = .13346 DF = 3 P = .988
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
If Deleted Simple Effect is DF L.R. Chisq Change Prob Iter
P1*P3 1 6.435 .0112 10
P2 1 574.104 .0000 2
_
* * * * * * * * H I E R A R C H I C A L L O G L I N E A R * * * * * * * *
Step 3
The best model has generating class
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P1*P3
P2
Likelihood ratio chi square = .13346 DF = 3 P = .988
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
* * * * * * * * H I E R A R C H I C A L L O G L I N E A R * * * * * * * *
The final model has generating class
The most 
parsimonious model 
P1*P3 is displayed
P2
The Iterative Proportional Fit algorithm converged at iteration 0.
The maximum difference between observed and fitted marginal totals is .320
and the convergence criterion is .389
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Observed, Expected Frequencies and Residuals.
Factor Code OBS count EXP count Residual Std Resid
P1 1
P2 1
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P3 1 6.0 6.6 -.62 -.24
P3 2 13.0 13.6 -.63 -.17
P2 2
P3 1 79.0 78.4 .60 .07
P3 2 162.0 161.4 .58 .05
P1 2
P2 1
P3 1 34.0 32.9 1.05 .18
P3 2 116.0 115.8 .20 .02
P2 2
P3 1 389.0 390.2 -1.18 -.06
P3 2 .0 .0 .00 .00
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Goodness-of-fit test statistics
Likelihood ratio chi square = .13346 DF (UNADJUSTED) = 3 P = .988
DF (ADJUSTED) = 2 P = .935
Pearson chi square = .13152 DF (UNADJUSTED) = 3 P = .988
DF (ADJUSTED) = 2 P = .936
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
_
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>Note # 13864
>UNADJUSTED DF have NOT been adjusted for structural or sampling zeroes.
>For ADJUSTED DF one degree of freedom is subtracted for each cell with an
>expected value of zero. The UNADJUSTED DF are an upper bound on the true
>DF, while the ADJUSTED DF may be an underestimate.
_
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
GENERAL LOGLINEAR ANALYSIS
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Data Information Information about the
analysis 
8 cases are accepted.
0 cases are rejected because of missing data.
799 weighted cases will be used in the analysis.
8 cells are defined.
1 structural zeros are imposed by design.
0 sampling zeros are encountered.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Variable Information
Factor Levels Value
P1 2
1.00
2.00
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P2 2
1.00
2.00
P3 2
1.00
2.00
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Model and Design Information
Model: Poisson
Design: Constant + P1 + P2 + P3 + P1*P3
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Correspondence Between Parameters and Terms of the Design
Parameter Aliased Term
1 Constant
2 [P1 = 1.00]
3 x [P1 = 2.00]
4 [P2 = 1.00]
5 x [P2 = 2.00]
6 [P3 = 1.00]
7 x [P3 = 2.00]
8 [P1 = 1.00]*[P3 = 1.00]
9 x [P1 = 1.00]*[P3 = 2.00]
10 x [P1 = 2.00]*[P3 = 1.00]
11 x [P1 = 2.00]*[P3 = 2.00]
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_
Note: 'x' indicates an aliased (or a redundant) parameter.
These parameters are set to zero.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Convergence Information
Maximum number of iterations: 20
Relative difference tolerance: .001
Final relative difference: .0008
Maximum likelihood estimation converged at iteration 2.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Table Information Observed and 
expected values in 
Observed Expected the contingency
Factor Value Count % Count % table
P1 1.00
P2 1.00
P3 1.00 6.00 ( .75) 6.60 ( .83)
P3 2.00 13.00 ( 1.63) 13.58 ( 1.70)
P2 2.00
P3 1.00 79.00 ( 9.89) 78.40 ( 9.81)
P3 2.00 162.00 ( 20.28) 161.42 ( 20.20)
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P1 2.00
P2 1.00
P3 1.00 34.00 ( 4.26) 32.82 ( 4.11)
P3 2.00 116.00 ( 14.52) 116.00 ( 14.52)
P2 2.00
P3 1.00 389.00 ( 48.69) 390.18 ( 48.83)
P3 2.00 .00 ( .00) .00 ( .00)
_
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
GENERAL LOGLINEAR ANALYSIS
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Table Information
Adj. Dev.
Factor Value Resid. Resid. Resid.
P1 1.00
P2 1.00
P3 1.00 -.60 -.26 -.24
P3 2.00 -.58 -.19 -.16
P2 2.00
P3 1.00 .60 .26 .07
P3 2.00 .58 .19 .05
P1 2.00
P2 1.00
P3 1.00 1.18 .35 .20
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P3 2.00 .00 .00 .00
P2 2.00
P3 1.00 -1.18 -.35 -.06
P3 2.00 . . .
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Goodness-of-fit Statistics
Chi-Square DF Sig.
Likelihood Ratio .1324 2 .9359
Pearson .1309 2 .9367
_
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
GENERAL LOGLINEAR ANALYSIS
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Parameter Estimates
Asymptotic 95% CI
Parameter Estimate SE Z-value Lower Upper
1 7.2290 .1705 42.41 6.89 7.56  ← This estimate will be  
2 -2.1450 .1781 -12.04 -2.49 -1.80 the log of the size of  
3 .0000 . . . . the hidden population
4 -2.4754 .1430 -17.31 -2.76 -2.20
5 .0000 . . . .
6 -1.2624 .1684 -7.49 -1.59 -.93
7 .0000 . . . .
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8 .5403 .2141 2.52 .12 .96
9 .0000 . . . .
10 .0000 . . . .
11 .0000 . . . .
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Covariance Matrix of Parameter Estimates
Parameter
1 2 4 6 8
1 .0291
2 -.0275 .0317
4 -.0204 .0189 .0204
6 -.0275 .0260 .0189 .0284
8 .0275 -.0317 -.0189 -.0284 .0459
Aliased parameters are not shown.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Correlation Matrix of Parameter Estimates
Parameter
1 2 4 6 8
1 1.0000
2 -.9048 1.0000
4 -.8387 .7404 1.0000
6 -.9568 .8669 .7829 1.0000
8 .7526 -.8318 -.6158 -.7866 1.0000
Aliased parameters are not show
